

Microglia activation by derepression of endogenous retroviruses drives inflammation and cellular senescence

Received: 1 July 2024

Accepted: 13 July 2026

Published online: 17 August 2026

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Aging-associated loss of chromatin compaction is linked to derepression of retrotransposable elements (RTEs) in mouse and human tissues. Whether such RTE transcription contributes to the microglia activation that is common in aged brains is unknown. Here, we show that DAXX, a histone chaperone and RTE repressor, is downregulated during aging, preserves microglia homeostasis and inhibits cellular senescence. Loss of *Daxx* in young-adult microglia drives a reactive phenotype marked by chromatin decompaction at RTEs, loss of homeostatic markers, cell cycle re-entry and behavioral changes. This state leads to DNA damage and microglial depletion, followed by replacement with DAXX-deficient/*Apoe*^{high} microglia displaying features of senescence. Sustained induction of senescence relies on promyelocytic leukemia protein, a DAXX-interacting factor and interferon target. Together, these findings highlight the importance of heterochromatin maintenance in preserving adult microglial identity and plasticity, with broader implications for brain homeostasis, healthy aging and behavior.

Loss of heterochromatin is a hallmark of aging and cellular senescence¹ and has been linked to derepression of repeat elements, including retrotransposable elements (RTEs)^{2–4}. In adult tissues, RTEs are silenced via multiple mechanisms, including loading of the histone variant H3.3 (refs. 5,6). RTEs are co-opted in the response to inflammatory stimuli via their enhancer function and are themselves targets of key proinflammatory transcription factors (TFs)⁷. More generally, RTE deregulation has been implicated in aging, neurodegenerative diseases, autoinflammatory conditions and cancer^{5,8–10}.

Microglia are the resident innate immune cells of the CNS¹¹, where they mediate surveillance against infections and various brain pathological states^{12–14}. During aging and in neurodegenerative conditions, microglia undergo transition from a homeostatic state to distinct reactive states^{15,16}, which have been reported as either beneficial or detrimental depending on the disease type and/or stage. These transitions are associated with profound alterations of the microglia transcriptome and their function^{16,17}. Although chromatin modifications have been suggested to modulate microglia development and activity^{18,19},

the impact of age-dependent decline in chromatin compaction in microglia remains mostly unexplored. In this respect, trimethylated lysine 27 histone 3 (H3K27me3) was linked to either an increased or decreased inflammatory response^{20–22}. Interestingly, loss of heterochromatin has been associated with senescence induced by pathogenic Tau²³ and to the ‘dark microglia’ state²⁴.

The H3.3 chaperone DAXX²⁵ acts as a repressor of RTEs of viral origin (hereafter referred to as long-terminal repeat RTEs (LTR-RTEs))^{4,26–28} via interaction with H3.3 and the H3K9 methyltransferase TRIM28–SETDB1 complex⁴. We have shown that loss of *Daxx* in hematopoietic progenitors causes a reduction in H3K9me3 and RTE derepression, leading to PU.1-mediated neutrophilia²⁷. Moreover, DAXX is upregulated in microglia following interferon- γ (IFN γ) stimulation²⁹, but the functional implications of its induction remain unknown.

In the present study, we unravel a role for DAXX in maintenance of the homeostatic state of adult microglia, with implications for our understanding of the relationship between loss of epigenetic barriers, innate immune cell senescence and aging-associated neuroinflammation.

✉ e-mail: xin.yan@dzne.de; paolo.salomoni@dzne.de

Results

Expression dynamics of RTEs and their regulators during maturation of microglia from development to adult stages

We sought to investigate the expression of RTEs and their regulators during development and in the adult brain. Microglia originate from yolk sac progenitors, which colonize the CNS and differentiate into specialized resident macrophages¹¹. By mining existing RNA sequencing (RNA-seq) datasets³⁰ and *k*-mean clustering analysis, we revealed dynamic regulation of LTR- and non-LTR-RTEs across developmental and adult stages (Fig. 1a). While the early-stage cluster E1 displayed higher RTE expression, the E2 cluster was enriched in both early and fetal microglia but was downregulated in adult microglia. By contrast, the adult microglia clusters (A1–A2) were enriched in both embryonic and adult microglia. In accordance with previous studies showing RTE deregulation during aging^{31,32}, a number of LTR-RTE subfamilies (based on ref. 33) were enriched in 24-month-old microglia (Fig. 1b).

We then assessed the expression of RTE regulators and associated factors across different brain cell types^{30,34} (Fig. 1c). The expression of *H3f3a* was higher at earlier stages, whereas *H3f3b* expression peaked at perinatal and adult stages until 3 months old (Fig. 1d). Both *H3f3a* and *H3f3b* were upregulated in 24-month-old microglia, in accordance with the known increase in H3.3 deposition at euchromatin in postmitotic cells in aged mice^{35,36}. Despite the slight increase in *Daxx* mRNA expression in 24-month-old microglia (Fig. 1d), *DAXX* protein levels were gradually downregulated in whole-brain lysates and in column-isolated microglia during aging (Fig. 1e), suggesting that *DAXX* is post-transcriptionally regulated, as previously proposed^{4,27}. Finally, other RTE repressors and heterochromatin regulators, such as *Suv39h*, *Dnmt3b*, *Setdb1* and *Trim28*, were enriched in early and premature microglia (Fig. 1d), whereas adult microglia displayed higher *Dnmt3a* and *Trdm1* expression, suggesting dynamic involvement of different RTE-silencing mechanisms during microglia maturation.

We recently showed an association between RTE expression and aging in blood cells from the Rhineland Study³⁷, a prospective study of healthy individuals during aging. We mined the same dataset to show that *DAXX* levels were associated with lower expression of nearly all RTE subfamilies, also after accounting for blood cell counts (Fig. 1f). The

sensitivity analysis, conducted using a dichotomous *DAXX* score in a subset of the Rhineland Study population ($N = 1,170$) supported these results (Fig. 1g). A rank-based gene set enrichment analysis revealed that genes whose expression levels were positively correlated with *DAXX* expression were negatively associated with terms related to translation and RNA processing (Extended Data Fig. 1a). These data demonstrate an inverse correlation between *DAXX* expression and RTEs in humans.

Finally, we examined whether *DAXX* expression was affected in a model of Alzheimer's disease (AD). To this end, we performed immunostaining on brain sections from 12-month-old APP/PS1 mice, where 6E10⁺ amyloid- β plaques in the cortex are surrounded by IBA1⁺ microglia (Extended Data Fig. 1b,c). *DAXX* intensity was reduced in microglia in both plaque and non-plaque areas, with the former showing a more marked reduction (Extended Data Fig. 1d,e). Accordingly, western blot analysis showed diminished *DAXX* protein levels, inversely correlating with the disease-associated microglia (DAM) marker ApoE (Extended Data Fig. 1f).


Together, these findings reveal dynamic modulation of RTEs and their regulators during brain development and aging and identify *DAXX* as an important RTE regulator in both human and mouse tissues during aging and in brain pathological states.


DAXX represses RTEs and IFN-stimulated genes at steady state and after inflammatory stimuli in microglia ex vivo

We next decided to investigate *DAXX* expression and regulation in microglia. In agreement with previous studies showing its induction following treatment with type I or II IFNs in cell lines³⁸, we showed that both lipopolysaccharide (LPS) and polyinosinic:polycytidylic acid (poly(I:C)) elevated *DAXX* protein levels in primary microglia, peaking at late time points (Extended Data Fig. 2a–d). Furthermore, RNA-seq data from primary microglia showed marked LPS-induced upregulation of *Daxx* expression at 6 h, in conjunction with other inflammatory and IFN-stimulated genes (ISGs), including *Stat1*, *Ifnb1*, *Isg15* and *Irf7* (Extended Data Fig. 2e,f). Finally, by using bone marrow-derived macrophages (BMDMs) from IFN α receptor knockout (*ifnar*-KO) mice, we showed that *DAXX* induction is dependent on IFN signaling (Extended Data Fig. 2g,h).

Fig. 1 | Dynamic expression of RTEs and RTE regulators in microglia during development, in the adult brain and during aging. **a**, Heat maps showing *k*-means clustering ($k = 5$) of dynamically expressed LTRs and non-LTRs in microglia isolated from the developing brain or CNS across embryonic, postnatal and adult stages (data from ref. 30; $n = 1$ mouse for E14.5 and E16.5, $n = 2$ mice per group for the rest). Clusters are named as early microglia cluster 1 (E1), E2, premature, adult microglia cluster 1 (A1) and A2 and are indicated on the left; mon, month; normcount, normalized count. **b**, Heat maps showing *k*-means clustering ($k = 5$) of dynamically expressed LTRs and non-LTRs in microglia isolated from 3- to 24-month-old mouse brains (data from ref. 33; $n = 4$ mice for 3 and 12 months, $n = 2$ mice for 6 months, $n = 3$ mice for 9 and 24 months, $n = 5$ mice for 16 months). Clusters are named as C1, C2, C3, C4 and C5 and are indicated on the left. **c**, Heat map showing the relative expression of RTE repressor genes across major brain cell types (data from ref. 34). **d**, Heat maps showing the relative expression of RTE repressor genes in microglia across embryonic (E), postnatal (P), adult and aging stages (data from refs. 30,33). **e**, Western blots and quantification analysis of *DAXX* expression in whole-brain lysates from 2-, 9- and 25-month-old mice ($n = 3$ mice for each age; data were analyzed by ordinary one-way analysis of variance (ANOVA), $F = 5.812$, $P = 0.0395$; Tukey's multiple comparisons test, $P_{9\text{ month versus }2\text{ month}} = 0.5353$, $P_{25\text{ month versus }2\text{ month}} = 0.0355$, $P_{25\text{ month versus }9\text{ month}} = 0.1449$) and in isolated microglia from brains of 4-, 9- and 24-month-old mice ($n = 3$ mice for each age; data were analyzed by ordinary one-way ANOVA, $F = 57.81$, $P = 0.0001$; Tukey's multiple comparisons test, $P_{9\text{ month versus }4\text{ month}} = 0.0005$; $P_{24\text{ month versus }4\text{ month}} = 0.0001$; $P_{24\text{ month versus }9\text{ month}} = 0.1213$). β -Actin served as a loading control; Fold ch., fold change. **f**, Volcano plots showing the association between expression levels of *DAXX* (on a continuous scale) and those of RTE subfamilies ($N = 2,922$) in a human cohort using multivariable linear regression models, while applying false discovery rate (FDR) correction to account for multiple comparisons; Model 1

(adjusted for age and sex): higher expression levels of *DAXX* were associated with lower expression levels of 782 (of 795) RTE subfamilies (FDR-adjusted two-sided $P < 0.05$); Model 2 (adjusted for age, sex and white and red blood cell counts): higher expression levels of *DAXX* were associated with lower expression levels of 785 (of 795) RTE subfamilies (FDR-adjusted two-sided $P < 0.05$). Each dot represents one RTE subfamily, with statistically significant associations (that is, FDR-adjusted two-sided $P < 0.05$) marked in red. The x axis shows the regression coefficients for the association of *DAXX* with each RTE subfamily, while the dashed red line represents the threshold for statistical significance. **g**, Volcano plots showing the association between expression levels of *DAXX* (categorized into low-*DAXX* versus high-*DAXX* groups based on the expression levels of *DAXX* falling within the 20% lowest or highest range of the population distribution, respectively; $N = 1,170$), using multivariable linear regression and applying FDR correction to account for multiple comparisons; Model 1 (adjusted for age and sex): the expression levels of 423 RTE subfamilies were higher in the low-*DAXX* group than in the high-*DAXX* group (FDR-adjusted two-sided $P < 0.05$); Model 2 (adjusted for age, sex and white and red blood cell counts): the expression levels of 467 RTE subfamilies were higher in the low-*DAXX* group than in the high-*DAXX* group (FDR-adjusted two-sided $P < 0.05$). Each dot represents one RTE subfamily, with statistically significant associations (that is, FDR-adjusted two-sided $P < 0.05$) marked in red. The x axis shows the regression coefficients for the association between *DAXX* expression group and each RTE subfamily, while the dashed red line represents the threshold for statistical significance. Abbreviations: Astr, astrocyte; Ctx, cortex; Endo, endothelial cells; GC, glial cells; Hipp, hippocampus; MGL, microglia; MOG, mature oligodendrocyte; OPC, oligodendrocyte progenitor cells; Sp, spinal cord. Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$ and *** $P < 0.001$; P_{adj} , adjusted P value.





To assess the impact of *Daxx* loss, we generated a tamoxifen (TAM)-inducible conditional knockout mouse line (Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl}) for *Daxx* ablation in tissue-resident macrophages and microglia³⁹. Incubation with 4-hydroxytamoxifen for 24 h led to *Daxx* recombination and reduced protein levels in Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} primary

microglia (Fig. 2a,b and Extended Data Fig. 3a), associated with induction CD68, a phagolysosome marker indicative of a microglia reactive state (Fig. 2c,d). RNA-seq analysis showed pronounced changes in gene expression in unstimulated cells (Fig. 2e and Extended Data Fig. 3b), with most deregulated genes representing loci upregulated by LPS in

Fig. 2 | Loss of *Daxx* in primary microglia triggers RTE activation and ISGs at steady state and prolongs expression upon stimulus. **a, b**, Representative confocal images of IBA1, DAXX and DAPI immunostaining (**a**) and quantification (**b**) of DAXX intensity in primary microglia isolated from *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* mice ($n = 3$ independent preparations per genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P = 0.02$); Rel., relative. **c, d**, Representative confocal images of IBA1, CD68 and DAPI immunostaining (**c**) and quantification (**d**) of CD68 intensity in primary microglia isolated from *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* mice ($n = 3$ independent preparations per genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P = 0.0467$). **e**, Heat map representing the top 100 differentially expressed IFN pathway genes in DAXX-deficient and control primary microglia under basal conditions or following 6-, 24- and 48-h LPS stimulation. **f**, Left, heat map representing the overlap between genes upregulated in DAXX-deficient microglia at steady state and genes induced by LPS stimulation in control microglia. Right, selected inflammatory genes from the overlapping gene set. **g**, Volcano plot showing differentially expressed genes in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* versus *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* primary microglia. Differential expression analysis was performed using DESeq2 with a two-sided Wald test. *P* values were adjusted for multiple testing using the Benjamini–Hochberg procedure. The vertical and horizontal dotted lines show the cutoff of fold change = ± 1.5 and adjusted $P = 0.01$, respectively. **h**, IFN β secretion measured by enzyme-linked immunosorbent assay (ELISA) in ex vivo cultured *Cx3cr1-Cre^{ERT2}*;

Daxx^{fl/fl} microglia and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* microglia under basal conditions or following 24 h of LPS treatment ($n = 3$ independent preparations per group; data were analyzed by ordinary two-way ANOVA, $F = 251.4$, $P < 0.0001$; Sidak's multiple comparisons test, $P_{\text{PBS}} > 0.9999$; $P_{\text{LPS}} < 0.0001$). **i**, GO analysis for upregulated genes in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* microglia compared to control microglia. Enrichment was assessed using a one-sided hypergeometric test with a Benjamini–Hochberg FDR correction for multiple comparisons; Neg., negative; Pos., positive; prod., production; replic., replication; Reg., regulation; Resp., response. **j**, Heat map showing *k*-means clustering ($k = 5$) of LPS-responsive LTR elements according to their expression in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* primary microglia under basal conditions or following 6, 24 and 48 h of LPS stimulation. Clusters are named C1, C2, C3, C4 and C5 and are indicated on the left. **k**, GO analysis for genes neighboring LTR elements in C2 and C4 identified in **j**. Statistical significance was determined using Genomic Regions Enrichment of Annotations Tool (GREAT), which applies a two-sided binomial test over genomic regions. **l**, Heat map showing gene expression neighboring the top 30 overexpressed intergenic LTRs in DAXX-deficient microglia at steady state and in LPS-stimulated control microglia; Nan, not applicable. **m**, Heat map showing expression of RTE repressor genes in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* primary microglia under basal conditions or following 6, 24 and 48 h of LPS stimulation. Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$ and *** $P < 0.001$; NS, not significant.

control microglia (Fig. 2f,g). IFN β levels were higher in DAXX-deficient microglia following LPS treatment, but not at steady state (Fig. 2h), suggesting that gene expression alterations are IFN β independent or rely on undetectable IFN β levels in the absence of a stimulus. Gene Ontology (GO) analysis revealed that genes upregulated in DAXX-deficient microglia at steady state were enriched in antiviral response and immune IFN β processing terms (Fig. 2i).

Daxx loss in *Rosa-Cre^{ERT2}*; *Daxx^{fl/fl}* BMDMs also led to increased expression of ISGs, such as *Stat1* and *Mda5*, the latter a gene encoding an RNA-sensing protein, without discernable effects on viability (Extended Data Fig. 3c–f). As in microglia, IFN β secretion was more pronounced in *Rosa-Cre^{ERT2}*; *Daxx^{fl/fl}* BMDMs following poly(I:C) or LPS treatment (Extended Data Fig. 3g). Pretreatment with a STAT1 pharmacological inhibitor reduced IFN β secretion in both genotypes (Extended Data Fig. 3g). While STAT1 protein expression was higher in *Rosa-Cre^{ERT2}*; *Daxx^{fl/fl}* BMDMs at both steady state and following stimulation, there was no net induction of STAT1 phosphorylation (Extended Data Fig. 3h,i). IFN β secretion remained higher in DAXX-deficient cells than in control cells up to 24 h (Extended Data Fig. 3j). Finally, TNF was augmented only at 24 h, suggesting an effect of DAXX loss on NF- κ B-mediated transcription (Extended Data Fig. 3j).

Fig. 3 | Deletion of *Daxx* in microglia leads to a reactive phenotype in vivo.

a, Representative confocal images of DAXX and IBA1 double immunostaining in brain sections from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice ($n = 3$ mice for each genotype), at 1 w.p.i. **b**, Western blot and quantification of DAXX, TRIM28 and H3.3 in microglia isolated from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 1 w.p.i. β -Actin served as a loading control ($n = 3$ mice for each genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P_{\text{DAXX}} = 0.0094$, $P_{\text{TRIM28}} = 0.0011$, $P_{\text{H3.3}} = 0.0029$). **c**, Western blots for DAXX expression in microglia isolated from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 0 d.p.i. and 8 w.p.i. ($n = 3$ mice for each genotype). β -Actin served as a loading control. **d**, Representative confocal images of IBA1 immunostaining in brain sections from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 3 d.p.i. **e**, Quantification of IBA1⁺ cells in the hippocampus of *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 3 d.p.i. ($n = 8$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 10$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*), 1 w.p.i. ($n = 9$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 13$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*), 3 w.p.i. ($n = 5$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 7$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*), 8 w.p.i. ($n = 4$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 5$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*) and 1 y.p.i. ($n = 3$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 5$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*); data were analyzed by ordinary two-way ANOVA, $F = 7.177$, $P < 0.0001$; Sidak's multiple comparisons test *P* values


Next, we assessed the impact of DAXX depletion on RTE expression. While LTR-RTEs peaked at 6 h and then returned to steady state levels in 4-hydroxytamoxifen-treated *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* microglia (Fig. 2j), in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* microglia, a subset of RTEs displayed prolonged expression (C2 and C4 clusters; Fig. 2j). By combining locus-specific analysis and GO analysis, we revealed that RTEs in C2 and C4 displayed coordinated induction with ISGs in response to inflammatory stimuli (Fig. 2k). Interestingly, a number of the RTE–ISG pairs induced by LPS in *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* cells were derepressed at steady state following *Daxx* loss (Fig. 2k,l). Finally, DAXX depletion correlated with the induction of other RTE repressors, including *Chaf1b*, *Setdb1*, *Dnmt1*, *Dnmt3a*, *H3f3a* and *H3f3b* (Fig. 2m), suggesting potential compensation for RTE silencing in *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* microglia.

Together, these findings suggest that DAXX ensures RTE and ISG repression in unstimulated cells, while its IFN β -dependent induction contributes to resolution of the inflammatory response.

Loss of *Daxx* in vivo causes altered microglial morphology, microglia depletion and astrogliosis

To investigate the impact of *Daxx* loss in microglia in vivo, *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* mice were treated with TAM and

for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* versus *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}*; $P_{3 \text{ d.p.i.}} = 0.0037$, $P_{1 \text{ w.p.i.}} < 0.0001$, $P_{3 \text{ w.p.i.}} = 0.0318$, $P_{8 \text{ w.p.i.}} = 0.4425$, $P_{1 \text{ y.p.i.}} = 0.9669$). **f, g**, Representative confocal images of IBA1 immunostaining (**f**) and morphological quantification (**g**) of IBA1⁺ cells in the CA1 region of the hippocampus from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 3 d.p.i. ($n = 4$ mice per group), 1 w.p.i. ($n = 4$ mice per group), 3 w.p.i. ($n = 4$ mice per group), 8 w.p.i. ($n = 6$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and $n = 8$ mice for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}*) and 1 y.p.i. ($n = 5$ mice per group; data were analyzed by ordinary two-way ANOVA with a Sidak's multiple comparisons test; *P* values for *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* versus *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}*: ramification index: $P_{3 \text{ d.p.i.}} < 0.0001$, $P_{1 \text{ w.p.i.}} < 0.0001$, $P_{3 \text{ w.p.i.}} < 0.0001$, $P_{8 \text{ w.p.i.}} = 0.2834$, $P_{1 \text{ y.p.i.}} = 0.3752$; number of branches: $P_{3 \text{ d.p.i.}} = 0.0457$, $P_{1 \text{ w.p.i.}} = 0.0011$, $P_{3 \text{ w.p.i.}} < 0.0001$, $P_{8 \text{ w.p.i.}} = 0.0007$, $P_{1 \text{ y.p.i.}} = 0.2958$; number of junctions: $P_{3 \text{ d.p.i.}} = 0.0267$, $P_{1 \text{ w.p.i.}} = 0.0005$, $P_{3 \text{ w.p.i.}} < 0.0001$, $P_{8 \text{ w.p.i.}} = 0.0005$, $P_{1 \text{ y.p.i.}} = 0.2962$). **h, i**, Representative confocal images (**h**) and quantification (**i**) of IBA1 and CD68 immunostaining in the hippocampus from *Cx3cr1-Cre^{ERT2}*; *Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2}*; *Daxx^{fl/fl}* mice at 3 w.p.i. ($n = 8$ mice for each genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P_{\text{CD68 intensity}} = 0.024$, $P_{\text{Pearson correlation}} = 0.0125$). The images on the far right in **h** show three-dimensional reconstructions of IBA1⁺ microglia with IBA1⁺ CD68⁺ double immunostaining. Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; AU, arbitrary units.



assessed at 0 days post-TAM treatment (d.p.i.), 1 d.p.i., 3 d.p.i., 1 week post-TAM treatment (1 w.p.i.), 3 w.p.i., 8 w.p.i. and 1 year post-TAM treatment (1 y.p.i.). Cre-mediated *Daxx* recombination was observed in column-isolated *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* microglia at 3 w.p.i., but not in the bone marrow, in accordance with the rapid turnover of peripheral macrophages (Supplementary Fig. 1a,b). DAXX downregulation was demonstrated across the entire time course from TAM treatment, correlating with reduced expression of two DAXX-interacting proteins, H3.3 (Fig. 3a–c), as we have previously shown²⁷, and TRIM28 (Fig. 3a–c).

Following *Daxx* loss, the number of IBA1⁺ microglia was reduced at 3 d.p.i. and 1 w.p.i. but then recovered from 3 w.p.i. onward (Fig. 3d,e). Concomitantly, microglia morphology acquired reactive features along with increased CD68 (Fig. 3f–i and Supplementary Fig. 1e), more markedly in the ventral CA1 (Supplementary Fig. 1d,e). Microglia morphology and numbers were unaffected at 0 d.p.i. in both genotypes (Supplementary Fig. 1c), excluding an effect of Cre or TAM treatment. Correlating with decreased microglia cellularity, the percentage of cleaved caspase-3⁺IBA1⁺ cells was increased following *Daxx* loss at 3 d.p.i. but not later (Supplementary Fig. 1f–i). Finally, the number of Ki67⁺IBA1⁺ proliferating microglia was also increased at the early time points (Supplementary Fig. 2a–c).

In accordance with the reported association between microglia activation and astrogliosis⁴⁰, glial fibrillary acidic protein (GFAP) immunoreactivity was increased in *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* brains from 1 w.p.i. onward, corroborated by western blots on whole-brain lysates (Supplementary Fig. 2d–f). Finally, the number of NeuN⁺ neurons, the area coverage of myelin basic protein (MBP) and the neurofilament marker SMI31 were not altered in the CA1 of *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* hippocampi at 3 w.p.i. and 8 w.p.i. (Supplementary Fig. 2g–j).

Collectively, *Daxx* loss leads to induction of a microglia reactive state and astrogliosis, which are associated with cell death and entry into the cell cycle.

Mice lacking microglial *Daxx* display reduced synaptic markers/puncta and behavioral alterations

Because reactive microglia may mediate synapse pruning and remodeling⁴¹, we assessed Bassoon⁺Homer1⁺ synaptic puncta and found a transient reduction following microglial *Daxx* loss (Fig. 4a,b), correlating with decreased synaptic protein expression in whole-brain lysates (Supplementary Fig. 2f). We then assessed whether these changes correlated with behavioral perturbations, given that dysfunctional microglia have been linked to altered behavior in mice, including anxiety-like phenotypes^{42,43}. We then performed a panel of tests to characterize different domains of mouse behavior at 8 w.p.i., when microglia numbers had recovered to control levels. *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice traveled longer distances in the open-field arena and spent slightly

reduced time exploring the center of the arena (Fig. 4c), suggesting increased anxiety. This is in agreement with the more pronounced changes in microglial morphology in the prefrontal cortex (Fig. 4h,i), a region implicated in fear and anxiety^{42,44}. Results from the elevated plus maze test also indicated anxiety-like behavior (Fig. 4d), with lack of discernible defects in locomotion (Fig. 4e). Finally, Barnes maze tests for spatial learning and memory function suggested that the motivation of *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice to search for another escape of the maze declined, indicating a potential stress-response search strategy or executive dysfunction. While the escape latency as well as the number of serial errors were unchanged (Fig. 4g), *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice spent more time in the target hole at probe day 14 (Fig. 4f,g), suggesting that they remember the target location more effectively, whereas their search strategy may result from anxiety-driven avoidance of alternative holes.

Overall, our findings suggest that altered microglia function following *Daxx* loss has implications for brain function and behavior.

Daxx loss causes early RTE upregulation and a biphasic gene expression response

Given the impact of microglial *Daxx* loss on tissue homeostasis and behavior, we decided to explore potential perturbations of the microglia transcriptome and chromatin landscape. Bulk RNA-seq data obtained from column-isolated microglia showed clear separation between control and DAXX-deficient cells by principal component analysis (PCA) across the different time points (Supplementary Fig. 3a). By performing *k*-means clustering, differentially expressed LTR-RTEs were separated into five clusters (C1–C5; Fig. 5a), with LTR-RTEs within C1 and C3 being induced starting from 0 d.p.i. and peaking at 3 d.p.i., while in C2, C4 and C5, LTR-RTEs were gradually inhibited until 3 d.p.i., followed by an increase at later stages. Of note, intergenic C1 and C3 LTR-RTEs were already upregulated at 0 d.p.i. in DAXX-deficient microglia (Fig. 5b). The gradual downregulation of RTEs at later stages after *Daxx* loss correlated with induction of the RTE repressors *Chaf1* and *Dnmt1* (Supplementary Fig. 3c), as also observed in vitro (Fig. 2m).

In contrast to RTE induction, alterations in endogenous gene expression were observed only from 1 d.p.i. and peaked at 3 d.p.i. and 1 w.p.i. (Fig. 5c and Supplementary Fig. 3b), suggesting that the primary effect of *Daxx* loss is on RTE expression. Data integration using published datasets⁴⁵ showed an overlap between differentially expressed genes in DAXX-deficient microglia and signatures characterizing embryonic and early postnatal microglia (C3 and C6; Fig. 5d and Supplementary Fig. 3d). Genes found in C6 embryonic microglia also contained canonical DAM genes, like *Apoe* and *Axl*⁴⁵ (Fig. 5d). Furthermore, differentially expressed genes in DAXX-deficient microglia overlapped with aging-dependent microglia signatures


Fig. 4 | Mice lacking microglial *Daxx* display synapse puncta reduction and alterations of behavior. Behavioral characterization of *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}* and *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice at 8 w.p.i. Each data point represents one animal. **a,b**, Representative confocal images (**a**) and quantification (**b**) of Bassoon and Homer1 immunostaining in the prefrontal cortex of *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}* mice at 3 d.p.i. ($n = 5$ mice for each genotype), 1 w.p.i. ($n = 5$ mice for each genotype), 3 w.p.i. ($n = 5$ mice for each genotype), 8 w.p.i. ($n = 5$ mice for each genotype) and 1 y.p.i. ($n = 4$ mice for each genotype; data were analyzed by ordinary two-way ANOVA with a Sidak's multiple comparisons test; P values for *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice versus *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}*: presynaptic puncta: $P_{3\text{d.p.i.}} = 0.0301$, $P_{1\text{w.p.i.}} = 0.0015$, $P_{3\text{w.p.i.}} = 0.006$, $P_{8\text{w.p.i.}} = 0.9238$, $P_{1\text{y.p.i.}} = 0.6803$; postsynaptic puncta: $P_{3\text{d.p.i.}} = 0.0049$, $P_{1\text{w.p.i.}} = 0.0226$, $P_{3\text{w.p.i.}} = 0.408$, $P_{8\text{w.p.i.}} = 0.3306$, $P_{1\text{y.p.i.}} = 0.9975$; colocalized puncta: $P_{3\text{d.p.i.}} = 0.0023$, $P_{1\text{w.p.i.}} = 0.0134$, $P_{3\text{w.p.i.}} = 0.0254$, $P_{8\text{w.p.i.}} = 0.5976$, $P_{1\text{y.p.i.}} = 0.7808$). **c**, Open-field test with travel distance and quantification of time spent in the center zone and in the perimeter zone ($n = 12$ mice for each genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P_{\text{Distance}} = 0.0452$, $P_{\text{Duration center}} = 0.1595$, $P_{\text{Duration perimeter}} = 0.1595$); Cum., cumulative. **d**, Elevated plus maze test showing time spent in the closed and open arms ($n = 14$ mice for each genotype; data were analyzed by two-tailed

unpaired Student's *t*-test, $P_{\text{Closed arms}} = 0.0073$, $P_{\text{Open arms}} = 0.0108$). **e**, Rotarod test assessed by latency to fall from the accelerating rotarod ($n = 14$ mice for each genotype; data were analyzed by two-tailed unpaired Student's *t*-test, $P = 0.5425$). **f**, Representative tracking plots from the Barnes maze probe trials on days 7 and 14. **g**, Barnes maze test showing escape latency, number of error trails and time spent at the target hole and target zone ($n = 14$ mice for each genotype; data were analyzed by two-way repeated-measures ANOVA with a Sidak's multiple comparisons test; P values for *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* mice versus *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}*: escape latency, $P_{\text{day 7}} = 0.9069$, $P_{\text{day 14}} = 0.9999$; number of error trails, $P_{\text{day 7}} = 0.9374$, $P_{\text{day 14}} = 0.3888$; target hole, $P_{\text{day 7}} = 0.7754$, $P_{\text{day 14}} = 0.0115$; target zone, $P_{\text{day 7}} = 0.7816$, $P_{\text{day 14}} = 0.9218$). **h,i**, Representative confocal images (**h**) and quantification (**i**) of IBA1⁺ cells in the prefrontal cortex of *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* and *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}* mice at 1 w.p.i. ($n = 4$ mice for each genotype), 8 w.p.i. ($n = 3$ mice for each genotype), 12 w.p.i. ($n = 7$ mice for each genotype) and 1 y.p.i. ($n = 5$ mice for each genotype; data were analyzed by ordinary two-way ANOVA, $F = 8.386$, $P = 0.0003$; Sidak's multiple comparisons test P values for *Cx3cr1-Cre^{ERT2};Daxx^{fl/fl}* versus *Cx3cr1-Cre^{ERT2};Daxx^{WT/WT}* mice: $P_{1\text{w.p.i.}} = 0.0011$, $P_{8\text{w.p.i.}} = 0.0809$, $P_{12\text{w.p.i.}} = 0.0117$, $P_{1\text{y.p.i.}} = 0.0333$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$ and ** $P < 0.01$.

(Supplementary Fig. 3d)³³. GO analysis showed that cell division/mitosis terms were enriched in DAXX-deficient microglia (Fig. 5e) but were restricted to 3 d.p.i. and 1 w.p.i. (Fig. 5e), in accordance with the peak in Ki67 positivity (Supplementary Fig. 2a–c). By contrast, immune

response/inflammation terms remained stable throughout the entire time course (Fig. 5e).

We then addressed whether DAXX-deficient cells would be transcriptionally similar to reconstituting microglia following CSF1R inhibition^{33,46}






Fig. 5 | Loss of *Daxx* in microglia in vivo causes derepression of RTEs and marked changes of the microglia transcriptome. **a, b**, Heat maps showing *k* component Gaussian mixture model clustering ($k = 5$) of differentially expressed LTRs (**a**) and intergenic LTRs (**b**) in microglia isolated from *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice compared to *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} mice from 0 d.p.i. to 1 y.p.i. Clusters are indicated on the left. **c**, Volcano plots showing the differentially expressed genes in in vivo microglia isolated from *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice compared to *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} mice from 0 d.p.i. to 1 w.p.i. Differential expression analysis was performed using DESeq2 with a two-sided Wald test, and *P* values were adjusted for multiple testing using the Benjamini–Hochberg procedure. The vertical and horizontal dotted lines show the cutoff of fold change = ± 1.5 and an adjusted *P* value of 0.01, respectively. **d**, Heat map showing changes in gene expression associated with the developing microglial phenotype (named C6, according to published datasets in Hammond et al.⁴⁵) in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia compared to in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} microglia from 0 d.p.i. to 1 y.p.i. **e**, GO analysis of differentially expressed genes (DEGs) in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia compared to *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} microglia from 1 d.p.i. to 1 y.p.i. Differential expression analysis was performed using a two-sided hypergeometric test via the clusterProfiler::compareCluster package, and *P* values were adjusted for genome-wide multiple comparisons using the Benjamini–Hochberg FDR method; comp., compound; ext., external; med., mediated. **f**, Heat map showing TF motif enrichment in open and closed differentially accessible regions (DARs) identified by ATAC-seq in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at 3 d.p.i. Regions are classified as intergenic (IR) or nonintergenic (NIR). Differential expression analysis was performed using a one-sided hypergeometric test against an automatically generated background

set of genomic sequences via HOMER software. **g**, Heat map showing TF motif analysis in LTR-overlapping DARs located in intergenic (interg) regions of *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at 3 d.p.i. The color grade represents $-\log_{10}(P\text{value})$ for each motif. Differential expression analysis was performed using a one-sided hypergeometric test against an automatically generated background set of genomic sequences via HOMER software; Decre., decreased; Incre., increased. **h**, GO analysis of genes near opened chromatin regions at 3 d.p.i. overlapped with LTRs in intergenic regions. Differential expression analysis was performed using a two-sided binomial test over genomic regions; Adap., adaptive; Def., defensive; mol., molecule; oxyg., containing, oxygen-containing; recomb., recombination. **i**, Heat map showing overlap between differential ATAC-seq peaks in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at 3 d.p.i. and enhancer regions associated with developmental microglial states (data from ref. 30). Differential expression analysis for each pairwise genomic intersection was performed using a two-sided Fisher's exact test via the 'bedtools fisher' command. **j**, Genome browser tracks showing ATAC-seq and RNA-seq signal at the *Apoe* locus in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at 3 d.p.i. Highlighted regions indicate developmental microglial enhancers (yellow) and the *Apoe* gene locus (purple); cCREs, candidate *cis*-regulatory elements. **k**, Heat map showing relative expression of gene signatures associated with distinct microglia states, including homeostatic, cell cycle, developmental (C6)⁴⁵, DAM⁷⁴ and IFN response. Datasets include *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} (*Daxx* KO) from 0 d.p.i. to 1 y.p.i., *Sall1*^{fl/fl}; *Sall1*^{fl/fl} (*Sall1* KO)⁵¹, poly(I:C)-stimulated wild-type microglia (p(IC)^{5h}, p(IC)^{12h}) and poly(I:C)-stimulated *Ifnar*-KO microglia (*Ifnar* KO + p(IC)). Abbreviations: A1, adult microglia cluster 1; A2, adult microglia cluster 2; E1, early microglia cluster 1; P, premicroglia; YS, yolk sac.

(Supplementary Fig. 3d). Repopulation-associated signatures were up mostly before the observed replenishment detected at 3 w.p.i., suggesting a potential regenerative state of DAXX-deficient microglia. We also assessed whether *Daxx* loss recapitulated an exhausted microglia phenotype following three rounds of depletion/reconstitution (3×DR) described in a previous study³³, which, unlike our current work, was run using female mice due to limited changes in the microglia transcriptome in male mice. Most of the differentially expressed genes from 3×DR female microglia displayed an opposite direction of change in DAXX-deficient microglia, while conversely a subset of 3×DR downregulated genes was upregulated in *Daxx*-KO microglia. Finally, differentially expressed genes that followed the same direction of change were mostly enriched at early time points (Supplementary Fig. 3d), before microglia pool replenishment. Finally, the genes from 3×DR that remained up until 8 w.p.i. and 1 y.p.i. mostly belonged to the DAM category. These findings suggest that DAXX-deficient microglia fail to clearly recapitulate exhausted microglia.

Because enzymatic digestion during microglia preparation induces stress and causes an aberrant transcriptional response⁴⁷, we performed microglia isolation using an inhibitor cocktail to

prevent transcription and translation⁴⁷ and assessed the expression of a number of homogenization-induced genes and DAM genes (Supplementary Fig. 3e). The inhibitor cocktail downregulated the expression of the artifactual signature genes only in control microglia and not in DAXX-deficient microglia, whereas in untreated DAXX-deficient cells, these genes were as low as in inhibitor-treated wild-type cells. DAM genes were induced following *Daxx* loss, but they were unaffected by the inhibitor cocktail, overall indicating that transcriptome perturbations following *Daxx* depletion are predominantly caused by *Daxx* loss rather than cell isolation-induced artifacts.

Together, our data show that microglial *Daxx* loss leads to early RTE upregulation, followed by loss of homeostatic gene expression, a transient reactive/developmental state and stable induction of DAM genes.

Increased chromatin accessibility at RTEs as well as developmental and aging-associated enhancers following *Daxx* loss

To assess the effect of *Daxx* depletion on the chromatin landscape, we performed assay for transposase-accessible chromatin using

Fig. 6 | *Daxx* deletion causes reduced H3K9me3 at LTR-RTEs in adult microglia. **a, b**, Average H3K9me3 (**a**) or H3.3 (**b**) read depth across transposable element subfamilies in microglia isolated from *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} mice ($n = 2$ mice for H3K9me3 and 3 mice for H3.3) and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice ($n = 3$ mice for H3K9me3 and 2 mice for H3.3). Read depth was quantified by 1× normalization (reads per genomic content) using University of California, Santa Cruz (UCSC)-tools bigWigAverageOverBed (v2). For each transposable element subfamily, the mean of mean0 (average over bases, with noncovered bases counting as zeroes) was calculated and visualized as box plots. Analysis included the 20 most abundant transposable element subfamilies in the mm39 UCSC RepeatMasker annotation, together with LTR subfamily Gypsy and IAP elements. Subsequent analysis focused on the transposable element subfamilies that were more prominently altered (in bold; *P* values were calculated using unpaired two-sided Student's *t*-tests for *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} versus *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT}, $P_{ERV1} = 0.0075$, $P_{ERVK} = 0.0122$, $P_{IAP} = 0.0273$, $P_{LTR(\text{rest})} = 0.0349$ and $P_{Satellite} = 0.0344$). Box plots show the median and first and third quartiles (hinges), and whiskers extend from the hinge to the smallest/largest value at most 1.5× the interquartile range. **c, d**, Heat maps and aggregate profiles of H3K9me3 and H3.3 enrichment across LTR subfamilies, including

ERV1 ($n = 69,131$), Gypsy ($n = 3,440$), IAP ($n = 30,005$), ERVK ($n = 370,031$), ERVL ($n = 113,067$), ERVL-MaLR ($n = 534,111$) and LTR (rest; $n = 15,284$). IAP elements exhibited the strongest H3K9me3 enrichment and a marked reduction of H3K9me3 signal in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia (*Daxx* KO) compared to *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} microglia (control (Ctrl)). Different color keys show different marks (for example, H3.3, H3K9me3); TE, transposable element. **e**, MA plots showing binding changes using DiffBind. Top, IAP elements ($n = 30,005$) displaying a reduction in H3K9me3 (not H3.3) in *Daxx*-KO microglia versus control microglia. Bottom, human microglia-specific enhancers and promoters (data from ref. 54). Differential binding changes of homologs were assessed using DiffBind (FDR < 0.05; strict settings). Statistical analysis was performed using a Wald test on generalized linear model coefficients (from the DESeq2 package). **f**, Heat maps and profiles of H3K9me3 and H3.3 enrichment across LTR clusters identified in Fig. 5a. **g**, Bar plot showing the proportion of differentially bound H3K9me3 peaks overlapping TSSs of individual transposable element subfamilies. Percentages are calculated relative to the total number of TSSs in each subfamily. **h**, Genome browser views of representative loci showing reduced H3K9me3 enrichment and H3.3 occupancy at RTEs in *Daxx*-KO microglia. Asterisks (*) indicate statistical significance: * $P < 0.05$.



sequencing (ATAC-seq) at 3 d.p.i. to capture early changes in chromatin accessibility. PCA revealed clear clustering according to genotype (Supplementary Fig. 3f), whereas motif enrichment analysis showed that regions that gained accessibility were enriched in AP-1-related motifs (Fig. 5f), consistent with a microglia reactive state^{48,49} (Fig. 5f). By contrast, intergenic LTR-RTEs gaining accessibility were enriched in the PU.1 motif (Fig. 5g), as in DAXX-deficient hematopoietic progenitors²⁷. GO analysis indicated that intergenic LTR-RTEs gaining accessibility were in close proximity to immune regulation genes and ISGs (Fig. 5h). By accessing published data⁴⁵, we showed that a subset of developmental enhancers (YS/E1 cluster) showed increased accessibility in DAXX-deficient microglia (Fig. 5i) and were close to deregulated ISGs and DAM genes, including regulatory regions within the *Ceacam19* locus downstream of *ApoE* (Fig. 5j and Supplementary Fig. 3g). By contrast, enhancers losing accessibility were associated with adult microglia (A1/A2 clusters) and in proximity to downregulated homeostatic genes, such as *Sall1*, *P2ry12*, *Cx3cr1* and *Mafb* (Supplementary Fig. 3h), correlating with *Sall1* super enhancer⁵⁰ reduced accessibility (Supplementary Fig. 3h).

By accessing published data on aged microglia³³, we found that a subset of open promoter regions in aged microglia showed increased accessibility also in DAXX-deficient microglia (Supplementary Fig. 4a), whereas over 60% of intergenic regions gaining accessibility in DAXX-deficient microglia were also open in 24-month-old microglia (Supplementary Fig. 4b). Although ETS motifs were mainly enriched in aged microglia (Supplementary Fig. 4c), DAXX-deficient microglia presented enrichment in AP-1 motifs (Supplementary Fig. 4c), including in the above-mentioned intersected intergenic regions (Fig. 5f).

Collectively, these data suggest that DAXX-deficient microglia acquire a chromatin state compatible with both developmental and aging-associated cell identities.

Loss of *Sall1* or viral mimicry signaling recapitulates some changes observed in DAXX-deficient microglia

Given the downregulation of homeostatic genes in DAXX-deficient microglia, we sought to examine potential transcriptional similarities between DAXX-deficient microglia and *Sall1* super enhancer-deficient microglia⁵⁰ (germline *Sall1* heterozygous endogenous KO (EKO) and *Sall1* EKO; Supplementary Fig. 4d). Indeed, we could demonstrate a significant overlap in gene expression between DAXX-deficient and *Sall1*-EKO microglia (Supplementary Fig. 4d,e). We then integrated our data with bulk RNA-seq data from *Cx3cr1*-Cre^{ERT2}; *Sall1*^{fl/fl} (*Sall1*-KO) mice⁵¹ and from in-house poly(I:C)-stimulated wild-type or *Ifnar*-KO microglia. We showed that the increase in cell cycle genes (1 d.p.i. to 1 w.p.i.) and C6/DAM signatures (3 d.p.i. to 1 y.p.i.), ISG induction (Fig. 5k) and downregulation of homeostatic genes in *Daxx*-KO microglia were in part recapitulated following deletion of *Sall1* itself⁵¹ or poly(I:C) treatment. Loss of *Ifnar* rescued homeostatic gene expression and reduced ISGs, whereas cell cycle genes were unaffected, and the gene encoding *Ki67* and most C6/DAM genes were further upregulated (apart from *ApoE*, *Axl*, *Cd74* and *Ms4a6*).

Intersection of differentially upregulated and downregulated RTEs in microglia following LPS (ex vivo) or poly(I:C) (in vivo) treatment identified commonly upregulated and downregulated RTEs across conditions and time points (Supplementary Fig. 4f). Notably, a large proportion of these RTEs was upregulated in *Daxx*-KO microglia starting from 1 d.p.i. and peaking at 3 d.p.i. A similar induction was observed in *Sall1*-KO microglia as well as in poly(I:C)-stimulated control microglia (Supplementary Fig. 4g). However, most of these inflammation-related RTEs were not affected by *Ifnar* loss following poly(I:C) treatment.

These data indicate that gene and RTE expression changes caused by *Daxx* loss are in part recapitulated following loss of *Sall1* expression or poly(I:C) treatment.

Daxx loss leads to reduced H3K9me3 at LTR-RTEs but no changes in H3.3 enrichment

Previous studies showed that the DAXX–TRIM28–SETDB1 complex plays a critical role in RTE silencing through induction of H3K9me3 (refs. 4, 52, 53) but that binding of DAXX to H3.3, rather than H3.3 deposition itself, appears to be required for this function, potentially via reciprocal regulation of their respective protein levels⁴ (Fig. 3b). CUT&Tag experiments on column-isolated *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia (Fig. 6) revealed that *Daxx* loss reduces H3K9me3 at several LTR-RTEs, most prominently at intracisternal particles (IAPs; Fig. 6a). Although H3.3 was found at LTR-RTEs and often together with H3K9me3, it was mostly unaffected following *Daxx* loss (Fig. 6b–d). MA plot analysis illustrated two groups of differential IAP–transcription start site (IAP–TSS) peaks between DAXX-deficient and control microglia, with a wider distribution in the control group (Fig. 6e). Furthermore, we found differentially reduced H3K9me3 deposition at enhancers conserved between mice and humans⁵⁴ in DAXX-deficient microglia (Fig. 6e). Importantly, by replotting deregulated LTR-RTEs (Fig. 5a), we observed reduced H3K9me3 marks at C1 in DAXX-deficient microglia (Fig. 6f), while H3.3 remained unchanged (Fig. 5a). By assessing the overall percentage of all LTR-RTEs, several subfamilies, including IAPs, displayed reduced H3K9me3 following *Daxx* loss (Fig. 6g). Interestingly, *Ccnd2* (encoding cyclin D2), *Mki67* and *Xrcc1* were upregulated following *Daxx* loss (Fig. 5k) and were found in proximity to H3.3/H3K9me3-marked LTR-RTEs, with H3K9me3 being reduced following *Daxx* loss (Fig. 6h). Motif analysis for IAP peaks with higher H3K9me3 binding showed enrichment in several specific motifs (Supplementary Fig. 5a).

Together, these findings suggest that DAXX regulates RTEs via H3K9 trimethylation without clear effects on H3.3 deposition.

Gene expression changes caused by *Daxx* loss are in part recapitulated in H3.3- and TRIM28-deficient cells

Our findings suggest that DAXX interaction with H3.3, rather than its loading, is critical for RTE silencing in microglia, as previously reported⁴. Thus, we decided to investigate the overall effects of *Hira* or *H3f3b* loss in microglia using TAM-inducible *H3f3a*/*H3f3b* and *Hira* conditional knockout mice. While microglial soma size was increased in the brains of *Rosa*-Cre^{ERT2}; *H3f3a*^{fl/fl}/*H3f3b*^{fl/fl} mice compared to those in *H3f3a*^{fl/fl}/*H3f3b*^{fl/fl} control mice, microglia numbers were unchanged (Supplementary Fig. 5b,c). By contrast, microglia-specific loss of *Hira* had no effect on either microglia morphology or number (Supplementary Fig. 5d,e). Bulk RNA-seq data⁵⁵ from the *H3f3a*/*H3f3b* double knockout (*H3.3*-DKO) RAW264.7 macrophage cell line (Supplementary Fig. 5f–h) showed that a number of genes that were altered in DAXX-deficient microglia were similarly affected in *H3.3*-DKO cells (Fig. 5c,k and Supplementary Fig. 5i,j). Interestingly, a number of ISGs were downregulated in *H3.3*-DKO cells (Supplementary Fig. 5j), suggesting that they may require H3.3 loading for expression. Finally, based on existing datasets^{52,53}, TRIM28-deficient neural progenitor cells (NPCs) and lymphocytes also showed a partial overlap with genes altered in DAXX-deficient cells (Fig. 5k and Supplementary Fig. 5k).

In conclusion, our data suggest a functional interaction with H3.3 and the TRIM28–SETDB1 complex, as previously reported in other models.

DAXX-deficient microglia enter into an aberrant state compatible with increased plasticity and DAM-like/*ApoE*^{high} features

To address whether the different signatures arising following *Daxx* loss define specific microglia subpopulations and/or coexist in the same microglia cell, we performed longitudinal single-cell RNA-seq (scRNA-seq) of microglia following *Daxx* loss. We first removed clusters containing either mixed cell populations or nonmicroglial/non-macrophage gene signatures and retained 13 clusters, of which only




Fig. 7 | DAXX-deficient microglia enter into a transient state of enhanced plasticity, followed by acquisition of DAM-like features. **a**, Uniform manifold approximation and projection (UMAP) and graph-based clustering of in vivo microglia isolated from Cx3cr1-Cre^{ERT2}; Daxx^{WT/WT} and Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} mice at 3 d.p.i., 1 w.p.i. and 8 w.p.i. **b**, A microglia trajectory was constructed using 7,878 of the 8,922 total cells, focusing on the 10 most interconnected clusters. Each cluster was identified and color coded. **c**, Trajectory analysis of Cx3cr1-Cre^{ERT2}; Daxx^{WT/WT} and Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} microglia. **d**, Bar graphs showing the percentage of microglia bearing single or double phenotypes (homeostasis, C6, IFN response, proliferation and DAM) in Cx3cr1-Cre^{ERT2}; Daxx^{WT/WT} and Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} mice at 3 d.p.i., 1 w.p.i. and 8 w.p.i. **e**, Violin plots showing gene expression of *Apoe*, AD risk, DAM-like, white matter injury and aging microglia signatures (OA2 and OA3) in in vivo microglia isolated from the brains of Cx3cr1-Cre^{ERT2}; Daxx^{WT/WT} and Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} mice at 3 d.p.i., 1 w.p.i. and 8 w.p.i. The black line indicates the median expression/module score calculated using the AddModuleScore() function in Seurat.

Statistical significance was assessed using pairwise two-sided Wilcoxon rank-sum tests and the `geom_signif` function (ggsignif R package) for the given comparisons, no correction for multiple testing; for *Apoe*, $P_{3\text{d.p.i.}} = 0.0021$, $P_{1\text{w.p.i.}} < 2.22 \times 10^{-16}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$; for AD risk genes, $P_{3\text{d.p.i.}} = 0.12$, $P_{1\text{w.p.i.}} = 2.9 \times 10^{-6}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$; for DAM-like markers, $P_{3\text{d.p.i.}} < 2.22 \times 10^{-16}$, $P_{1\text{w.p.i.}} < 2.22 \times 10^{-16}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$; for white matter injury microglia, $P_{3\text{d.p.i.}} < 2.22 \times 10^{-16}$, $P_{1\text{w.p.i.}} < 2.22 \times 10^{-16}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$; for OA2, $P_{3\text{d.p.i.}} < 2.22 \times 10^{-16}$, $P_{1\text{w.p.i.}} < 2.22 \times 10^{-16}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$; for OA3, $P_{3\text{d.p.i.}} < 2.22 \times 10^{-16}$, $P_{1\text{w.p.i.}} < 2.22 \times 10^{-16}$, $P_{8\text{w.p.i.}} < 2.22 \times 10^{-16}$. **f**, Heat map of the top 50 age-associated markers calculated from a published aging microglia data set³³ across all cells of our scRNA-seq data set ($n = 10,172$ cells). The overlap of all age-associated markers with the markers from Cx3cr1-Cre^{ERT2}; Daxx^{fl/fl} versus Cx3cr1-Cre^{ERT2}; Daxx^{WT/WT} microglia ($n = 492$ cells; 68.05%; adjusted $P < 0.05$; average $\log_2$ (fold change > 0)) is highly significant: $P = 2.2 \times 10^{-16}$, odds ratio = 16.42 (two-sided Fisher's exact test for count data). Asterisks (*) indicate statistical significance: ** $P < 0.01$ and *** $P < 0.001$; MT, mitochondrial; WM, white matter.

C6 showed a nonmicroglial macrophage-like signature (Fig. 7a and Extended Data Fig. 4a,b). DAXX-deficient microglia clustered separately from wild-type microglia at all time points, whereas 3 d.p.i. and 1 w.p.i. DAXX-deficient microglia clustered together but separately from 8 w.p.i. DAXX-deficient microglia (Fig. 7a). To further assess the dynamics of transcriptional changes, we constructed a microglia trajectory focusing on the most interconnected clusters (C0–C5, C7–C9 and C12; Fig. 7b) and built separate trajectories for control and DAXX-deficient cells (Fig. 7c) as the cell distribution within each cluster for the two genotypes, using root clusters based on the highest percentage of cells at 3 d.p.i. (Extended Data Fig. 4c,d). When cells were organized along each trajectory (pseudotime; Fig. 7c), DAXX-deficient microglia followed a trajectory starting from ISG^{high} cells, which first branched off toward Ki67^{high} cells (C8) and then toward *P2ry12*^{high}*Sall1*^{high} cells (C1 and C12). This was followed by another bifurcation in C12, with cells either remaining *P2ry12*^{high}*Sall1*^{high} (C9, C4, C0 and C3) or becoming *Apoe*^{high}*H2*^{high} (C2 and C7). By contrast, control microglia retained mostly homeostatic features (*P2ry12*^{high}*Sall1*^{high}), with a subset of cells following a trajectory either toward Ki67^{high}IFN^{high} (reactive) or *Apoe*^{high}*H2*^{high} cells (DAMs). In line with bulk RNA-seq data, 3 d.p.i. and 1 w.p.i. microglia displayed loss of homeostatic markers and gain of ISG and proliferation/regeneration signatures (Extended Data Fig. 4e–g). Finally, 3 d.p.i. and 1 w.p.i. DAXX-deficient microglia resembled embryonic day 14.5 (E14.5) microglia⁴⁵ and were enriched in G2/M phase genes, compatible with cell cycle arrest or enrichment in this phase (Extended Data Fig. 4f,h).

Although most DAXX-deficient microglia displayed reduced expression of homeostatic genes at 3 d.p.i. (84%), which were partially restored at 8 w.p.i., acquisition of the C6 signature was detected in most cells (92%) and was stable over time (Fig. 7d). The percentage of cells positive for the IFN signature was 77% at 3 d.p.i. and 37% at 1 w.p.i. in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice (Fig. 7d). Approximately 30% of total DAXX-deficient microglia displayed coexistence of C6/proliferation signatures at 3 d.p.i. and 1 w.p.i. (Fig. 7d). Furthermore, we found that the percentage of DAM⁺C6⁺ microglia increased from 17% at 3 d.p.i. to nearly 66% at 8 w.p.i. in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice, with 8 w.p.i. DAXX-deficient microglia also showing upregulation of major histocompatibility complex class II (MHC II)-related genes (Fig. 7d and Supplementary Fig. 6a). Via integration of published data⁴⁵, we showed that 3 d.p.i. and 1 w.p.i. DAXX-deficient microglia resembled injured white matter microglia and aged microglia (OA2 and OA3; Fig. 7e). Additionally, DAXX-deficient microglia also expressed C6 embryonic microglia genes, which comprise DAM and brain border-associated macrophage progenitor markers (Supplementary Fig. 6b). Of note, DAXX-deficient microglia progressively upregulated *Apoe* expression and the expression of other AD risk genes (Fig. 7e and Extended Data Fig. 5a). Based on pseudotime

analysis (Extended Data Fig. 5b,c), reduced *Apoe* expression drove the trajectory toward *P2ry12*^{high}*Sall1*^{high} cells (C0), whereas higher *Apoe* expression drove the trajectory toward *H2*^{high} cells (C2 and C7; Extended Data Fig. 5c). Finally, we found that the top 50 microglial genes from 24-month-old mice³³ were enriched in the 3 d.p.i. and 1 w.p.i. DAXX-deficient microglia, of which some (for example, *Apoe* and *H2*) remained up until 8 w.p.i. (Fig. 7f).

Overall, these data suggest that DAXX deficiency leads to acquisition of an aberrant state displaying coexistence of reactive and DAM signatures, followed by the emergence of a stable DAM-like/*Apoe*^{high} state.

Daxx downregulation leads to enhanced lysosomal ApoE expression and dystrophic neurites in older mice

To validate APOE induction at the protein level, we performed immunostaining and found that 1 y.p.i. DAXX-deficient microglia showed accumulation of structures containing ApoE and LAMP1 in both the cell body and processes (Extended Data Fig. 5d,e and Supplementary Fig. 7a), indicating alterations in phagocytosis. ApoE accumulation was not observed in GFAP⁺ cells (Supplementary Fig. 7b). We also showed SMI31⁺ aggregated neurites in the CA1 at 1 y.p.i. (Extended Data Fig. 5f). Finally, DAXX-deficient microglia displayed a transcriptional profile similar to amyloid plaque-associated microglia (XO4⁺)⁵⁶ and late-onset AD microglia (Supplementary Fig. 7c).

We found that 34 upregulated genes were shared across DAXX-deficient microglia, NPCs and bone marrow (KLS) progenitors²⁷ (Extended Data Fig. 6a,b), including *Apoe*, *Lamp1* and *Cdkn1a* (Extended Data Fig. 6c), supported by GO analysis revealing vacuolar transport, cell cycle and immune terms (Extended Data Fig. 6d). Reintroduction of wild-type *Daxx* into DAXX-deficient NPCs led to reduced *Apoe* expression (Extended Data Fig. 6e). Finally, a number of cis-regulatory elements in the *Apoe* locus displayed increased acetylated H3K27 following *Daxx* loss in KLS progenitors (Extended Data Fig. 6e).

Together, these results suggest a potential direct role for DAXX in regulation of *Apoe* expression and a phagocytic gene program across cell types.

Daxx loss causes induction of DNA damage markers, p53 targets and a senescence program

We sought to explore the potential association between the cell death phenotype and loss of genomic integrity. Indeed, *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia displayed increased DNA damage response (DDR)/p53/Cyclin-dependent kinase inhibitors (Cdkis) signatures between 1 d.p.i. and 1 w.p.i. (Fig. 8a), whereas p53 target genes involved in apoptosis (*Bax* and *Bak*), growth arrest/senescence (*Cdkn1a* and *Pml*) and the senescence-associated secretory phenotype were induced from 1 d.p.i.

Fig. 8 | DAXX-deficient microglia present DNA damage and PML-dependent cellular senescence.

a, Heat map showing the relative expression of gene signatures associated with distinct microglia states, including DDR, p53/Cdkis and senescence-associated secretory phenotype. Datasets include *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} (*Daxx* KO) from 0 d.p.i. to 1 y.p.i., *Sall1*-Cre^{ERT2}; *Sall1*^{fl/fl} (*Sall1* KO)⁵¹, poly(I:C)-stimulated wild-type microglia (p(IC)^{5h}), p(IC)^{12h} and poly(I:C) stimulated *Ifnar*-KO microglia (*Ifnar* KO + p(IC)). **b**, Western blot and quantification of DAXX, PML, phospho-p53 (p-p53), γH2AX and H2AX in microglia isolated from *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} (control) and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} (*Daxx*-KO) mice at 3 d.p.i. β-Actin served as the loading control (*n* = 4 mice per group; data were analyzed by two-tailed unpaired Student's *t*-test, $P_{\text{DAXX}} = 0.024$, $P_{\text{PML}} = 0.0054$, $P_{\text{p-p53}} = 0.0365$, $P_{\gamma\text{H2AX}} = 0.0197$, $P_{\text{H2AX}} = 0.2824$, $P_{\beta\text{-actin}} = 0.9935$); FC, fold change. **c,d**, Representative confocal images (**c**) and quantification (**d**) of co-staining for SA-β-Gal activity and IBA1 in the hippocampus of *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice from 3 d.p.i. to 8 w.p.i. (3 d.p.i. and 1 w.p.i.: *n* = 3 mice for each genotype; 8 w.p.i.: *n* = 4 mice for each genotype; data were compared by two-tailed unpaired Student's *t*-test, $P_{3\text{d.p.i.}} = 0.0086$, $P_{1\text{w.p.i.}} = 0.0094$, $P_{8\text{w.p.i.}} = 0.0495$). **e,f**, Representative confocal images of IBA1 immunostaining (**e**) and morphological quantification (**f**) of IBA1⁺

cells in the hippocampus of *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} mice (*n* = 3 mice), *Cx3cr1*-Cre^{ERT2}; *Pml*^{fl/fl} mice (*n* = 4 mice), *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice (*n* = 3 mice) and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl}*Pml*^{fl/fl} mice (*n* = 3 mice) at 8 w.p.i. (data were analyzed by ordinary one-way ANOVA with a Tukey's multiple comparisons test; for number of IBA1 cells: $F = 19.10$, $P_{\text{WT versus Pml KO}} = 0.9207$, $P_{\text{WT versus Daxx/Pml DKO}} = 0.0012$, $P_{\text{Pml versus Daxx/Pml DKO}} = 0.0025$, $P_{\text{Daxx KO versus Daxx/Pml DKO}} = 0.0012$; for ramification: $F = 14.62$, $P_{\text{WT versus Daxx KO}} = 0.0281$, $P_{\text{WT versus Daxx/Pml DKO}} = 0.0011$, $P_{\text{Pml versus Daxx/Pml DKO}} = 0.0023$, $P_{\text{Daxx KO versus Daxx/Pml DKO}} = 0.1563$; for number of branches: $F = 8.073$, $P_{\text{WT versus Daxx/Pml DKO}} = 0.0114$, $P_{\text{Pml versus Daxx/Pml DKO}} = 0.0107$, $P_{\text{Daxx KO versus Daxx/Pml DKO}} = 0.3785$). **g,h**, Representative confocal images (**g**) and quantification (**h**) of co-staining for β-galactosidase activity and IBA1 in the hippocampus of *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} mice (*n* = 3 mice), *Cx3cr1*-Cre^{ERT2}; *Pml*^{fl/fl} mice (*n* = 4 mice), *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice (*n* = 3 mice) and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl}*Pml*^{fl/fl} mice (*n* = 3 mice) at 8 w.p.i. (data were analyzed by ordinary one-way ANOVA, $F = 6.6$, $P = 0.0119$; Tukey's multiple comparisons test: $P_{\text{WT versus Pml KO}} = 0.754$, $P_{\text{WT versus Daxx KO}} = 0.0142$, $P_{\text{WT versus Daxx/Pml DKO}} = 0.9843$, $P_{\text{Daxx KO versus Pml KO}} = 0.0415$, $P_{\text{Daxx KO versus Daxx/Pml DKO}} = 0.0237$). Data are presented as mean ± s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

DAXX-deficient microglia (Fig. 8b), correlating with an increased percentage of γ H2AX⁺IBA1⁺ cells and abnormal microglial nuclear morphology (Extended Data Fig. 7c–e). No DNA damage or DDR was observed in either Cre⁺ wild-type controls or DAXX-deficient cells at 0 d.p.i. (Fig. 8a), arguing against Cre or TAM artefactual effects. Finally, *Daxx* loss led to an increase in senescence-associated β -galactosidase⁺ (SA- β -Gal⁺) microglia, substantiating our gene expression data (Fig. 8c,d).



Induction of senescence following *Daxx* ablation is dependent on the nuclear scaffold protein PML

We next sought to investigate potential mechanisms underlying induction of cellular senescence following *Daxx* loss. PML, a DAXX interactor involved in regulation of senescence and the essential component of PML nuclear bodies^{57–59}, was induced following *Daxx* ablation in microglia and BMDMs (Fig. 8b and Extended Data Fig. 7a,f,g). While *Cx3cr1*-Cre^{ERT2}-mediated deletion of *Pml* alone did not alter microglial number or morphology (Fig. 8e,f and Extended Data Fig. 8a,b), the hippocampus of TAM-treated *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl}; *Pml*^{fl/fl} (*Daxx*/*Pml* DKO) mice at 8 w.p.i. showed increased numbers of microglia and CD68 expression and reduced ramification index, suggesting a more reactive phenotype (Fig. 8e,f and Extended Data Fig. 8a,c–e). Moreover, Ki67⁺ microglia were increased in *Daxx*/*Pml* DKO mice compared to in other genotypes at 1 w.p.i., but not later (Supplementary Fig. 8a–d). Finally, at 8 w.p.i., the number of SA- β -Gal⁺ cells in *Daxx*/*Pml* DKO mice was reduced compared to in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} mice (Fig. 8e–h).

These findings suggest that PML limits the expansion of replenishing microglia following *Daxx* loss via maintenance of a senescence phenotype.

Daxx overexpression inhibits ApoE expression and cellular senescence in a replicative senescence model

We decided to explore whether DAXX is sufficient to inhibit cellular senescence using a replicative senescence model based on extended culturing of embryonic NPCs infected with a *Daxx* lentiviral vector (*Daxx*-OE NPCs) or an empty vector (EV NPCs; Extended Data Fig. 9a,b). DAXX levels decreased with increasing passages in both EV and *Daxx*-OE NPCs but remained higher in *Daxx*-OE cells (Extended Data Fig. 9a,b). While the percentage of SA- β -Gal⁺ cells, γ H2AX intensity and ApoE expression gradually increased in EV NPCs through passaging, these markers were reduced in *Daxx*-OE NPCs from postnatal day 13 (P13) onward (Extended Data Figs. 9c,d and 10a–d), along with *ApoE* and *Cdkn1a* (Extended Data Fig. 10e).

Collectively, these data indicate that overexpression of *Daxx* is sufficient to inhibit cellular senescence in NPCs and to suppress *ApoE* expression in a replicative senescence model.

Discussion

In the present study, we link maintenance of chromatin compaction at RTEs by the H3.3 chaperone DAXX to regulation of microglia identity and function in the adult brain. An inverse correlation between DAXX and RTE expression was demonstrated in peripheral blood samples of a large group of community-dwelling individuals, validating the RTE-repressive role of DAXX in human settings. Longitudinal assessment of these individuals displaying increased RTE levels would be an obvious future development.

We advance a model whereby DAXX represses RTE repression at steady state in microglia, whereas following exposure to activating stimuli, DAXX is induced in an IFN-dependent manner to re-silence RTEs and restrict the inflammatory response. In agreement with this model, loss of DAXX causes chronic RTE derepression and aberrant proinflammatory signaling, with implications for immune cell function and tissue homeostasis. Furthermore, we propose that DAXX contributes to the epigenetic barrier insulating microglia cell identity in the adult. In this respect, *Daxx* loss leads to a transient state, where multiple gene expression signatures coexist within the same cell, potentially reflecting enhanced plasticity. In agreement with our findings, recent studies suggest that replenishment of microglia in depletion models is due to reversion to a state permissive for expansion⁶⁰. How proliferation and cell death are functionally related in adult microglia remains poorly understood. Based on our findings, we envision that microglia carrying chromatin decompaction lose homeostatic features via lowering of the epigenetic barrier and entry into a developmental-like state characterized by cell cycle entry.

However, most of these microglia would be unable to complete cell division due to induction of DNA damage, leading to cell death or cellular senescence, as observed in the context of replication/mitotic stress following oncogenic activation⁶¹. One could also speculate that due to aging-associated loss of heterochromatin, microglia would be more susceptible to DNA damage, especially when they respond to stimuli such as inflammation, which would promote cell cycle entry. Notably, cellular senescence has been associated with microglia dysfunction during aging also in other studies^{31,33}, whereas loss of heterochromatin itself can induce cellular senescence⁶². Finally, HERVK elements have been suggested to reinforce cellular senescence during aging⁸. What remains to be understood is what the source of replenishment of the microglia pool is following *Daxx* loss. In this respect, we cannot exclude that migration of microglia from other regions contributes to this phenomenon, as suggested by others with respect to border-associated macrophages⁶³.

We then showed that the DAXX-interacting and IFN-responsive factor PML is responsible for sustained maintenance of the senescence phenotype following *Daxx* deletion. In agreement with this, concomitant DAXX and PML inactivation in microglia led to increased microglia cell numbers after the replenishment phase. However, further, potentially intertwined, mechanisms might also be involved. In this respect, recent studies showed that secreted ApoE induces senescence in neurons and neutrophils, potentially via a TREM2-dependent mechanism^{64,65}. Notably, ApoE promotes degradation of TRIM28 and destabilization of heterochromatin for induction of senescence⁶⁶. Further investigation is required to explore the functional involvement of ApoE in regulation of microglial heterochromatin, as well as its potential interplay with PML.

Would the acquisition of DAM-like and senescence features in our model have a detrimental or protective impact on brain homeostasis? On one hand, microglial DAXX loss leads to changes in mouse behavior, which are compatible with an anxiety-like phenotype. This is consistent with a recent report implicating DAXX as risk factor for anxiety disorders in humans⁶⁷. With respect to aging and aging-associated diseases, ApoE protein colocalized with the lysosomal marker LAMP1 in DAXX-deficient microglia, a phenotype also observed around plaques in an AD model. These structures may also constitute phagocytosed dystrophic neurites, which have been shown to be positive for LAMP1 in AD models⁶⁸. These changes are associated with the presence of what appear to be axonal aggregates positive for phosphorylated neurofilament, suggesting altered protein quality control and/or phagocytosis. Furthermore, a previous study showed that microglia positive for ARG1 and ApoE also display phagocytic inclusions, like in DAXX-deficient cells⁶⁹. Interestingly, we observed induction of LAMP1 along with genes involved in vesicle trafficking following *Daxx* loss also in NPCs and hematopoietic progenitors, suggesting that altered phagocytic function is a key consequence of DAXX impairment. A DAXX–lysosome molecular axis is of interest considering that alterations of lysosomes are fundamental events in aging and aging-associated conditions⁷⁰. Finally, the emerging role of both DAXX and PML^{71–73} in inhibition of protein aggregation might also contribute to maintenance of (nuclear) proteostasis in microglia during aging, a further line of research arising from our study.

Overall, our work provides evidence for heterochromatin maintenance and RTE silencing as epigenetic barriers against perturbations of microglial cell identity and induction of senescence, with implications for our understanding of microglia biology in health and disease.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41593-026-02404-y>.

References

- Lee, J.-H., Kim, E. W., Croteau, D. L. & Bohr, V. A. Heterochromatin: an epigenetic point of view in aging. *Exp. Mol. Med.* **52**, 1466–1474 (2020).
- Trono, D. Transposable elements, polydactyl proteins, and the genesis of human-specific transcription networks. *Cold Spring Harb. Symp. Quant. Biol.* **80**, 281–288 (2015).
- He, Q. et al. The DAXX/ATRX complex protects tandem repetitive elements during DNA hypomethylation by promoting H3K9 trimethylation. *Cell Stem Cell* **17**, 273–286 (2015).
- Hoelper, D., Huang, H., Jain, A. Y., Patel, D. J. & Lewis, P. W. Structural and mechanistic insights into ATRX-dependent and -independent functions of the histone chaperone DAXX. *Nat. Commun.* **8**, 1193 (2017).
- Gorbunova, V. et al. The role of retrotransposable elements in ageing and age-associated diseases. *Nature* **596**, 43–53 (2021).
- Wang, C. et al. Reprogramming of H3K9me3-dependent heterochromatin during mammalian embryo development. *Nat. Cell Biol.* **20**, 620–631 (2018).
- Chuong, E. B., Elde, N. C. & Feschotte, C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. *Science* **351**, 1083–1087 (2016).
- Liu, X. et al. Resurrection of endogenous retroviruses during aging reinforces senescence. *Cell* **186**, 287–304 (2023).
- Volkman, H. E. & Stetson, D. B. The enemy within: endogenous retroelements and autoimmune disease. *Nat. Immunol.* **15**, 415–422 (2014).
- Evering, T. H., Marston, J. L., Gan, L. & Nixon, D. F. Transposable elements and Alzheimer's disease pathogenesis. *Trends Neurosci.* **46**, 170–172 (2023).
- Mass, E. et al. Specification of tissue-resident macrophages during organogenesis. *Science* **353**, aaf4238 (2016).
- Li, Q. & Barres, B. A. Microglia and macrophages in brain homeostasis and disease. *Nat. Rev. Immunol.* **18**, 225–242 (2018).
- Thion, M. S., Ginhoux, F. & Garel, S. Microglia and early brain development: an intimate journey. *Science* **362**, 185–189 (2018).
- Lazarov, T., Juarez-Carreño, S., Cox, N. & Geissmann, F. Physiology and diseases of tissue-resident macrophages. *Nature* **618**, 698–707 (2023).
- Bartels, T., De Schepper, S. & Hong, S. Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. *Science* **370**, 66–69 (2020).
- Keane, L. et al. mTOR-dependent translation amplifies microglia priming in aging mice. *J. Clin. Invest.* **131**, e132727 (2021).
- Colonna, M. & Brioschi, S. Neuroinflammation and neurodegeneration in human brain at single-cell resolution. *Nat. Rev. Immunol.* **20**, 81–82 (2020).
- Datta, M. et al. Histone deacetylases 1 and 2 regulate microglia function during development, homeostasis, and neurodegeneration in a context-dependent manner. *Immunity* **48**, 514–529 (2018).
- Wendeln, A.-C. et al. Innate immune memory in the brain shapes neurological disease hallmarks. *Nature* **556**, 332–338 (2018).
- Ayata, P. et al. Epigenetic regulation of brain region-specific microglia clearance activity. *Nat. Neurosci.* **21**, 1049–1060 (2018).
- Zhang, X. et al. Macrophage/microglial EZH2 facilitates autoimmune inflammation through inhibition of SOCS3. *J. Exp. Med.* **215**, 1365–1382 (2018).
- Das, A. et al. RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to inflammation mediated by the selective jumoni H3K27 demethylase inhibitor. *Sci. Rep.* **7**, 6554 (2017).
- Karabag, D. et al. Characterizing microglial senescence: Tau as a key player. *J. Neurochem.* **166**, 517–533 (2023).
- Flury, A. et al. A neurodegenerative cellular stress response linked to dark microglia and toxic lipid secretion. *Neuron* **113**, 554–571 (2025).
- Filipescu, D., Szenker, E. & Almouzni, G. Developmental roles of histone H3 variants and their chaperones. *Trends Genet.* **29**, 630–640 (2013).
- Wasyliszen, A. R. et al. DAXX maintains endogenous retroviral silencing and restricts cellular plasticity in vivo. *Sci. Adv.* **6**, eaba8415 (2020).
- Gerber, J. P. et al. Aberrant chromatin landscape following loss of the H3.3 chaperone DAXX in haematopoietic precursors leads to PU.1-mediated neutrophilia and inflammation. *Nat. Cell Biol.* **23**, 1224–1239 (2021).
- Elsässer, S. J., Noh, K.-M., Diaz, N., Allis, C. D. & Banaszynski, L. A. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. *Nature* **522**, 240–244 (2015).
- Yun, H. J. et al. DAXX mediates activation-induced cell death in microglia by triggering MST1 signalling. *EMBO J.* **30**, 2465–2476 (2011).
- Matcovitch-Natan, O. et al. Microglia development follows a stepwise program to regulate brain homeostasis. *Science* **353**, aad8670 (2016).
- De Cecco, M. et al. L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* **566**, 73–78 (2019).
- Van Meter, M. et al. SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age. *Nat. Commun.* **5**, 5011 (2014).
- Li, X. et al. Transcriptional and epigenetic decoding of the microglial aging process. *Nat. Aging* **3**, 1288–1311 (2023).
- Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci.* **34**, 11929–11947 (2014).
- Piazzesi, A. et al. Replication-independent histone variant H3.3 controls animal lifespan through the regulation of pro-longevity transcriptional programs. *Cell Rep.* **17**, 987–996 (2016).
- Banaszynski, L. A. et al. HIRA-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. *Cell* **155**, 107–120 (2013).
- Talevi, V. et al. Age and sex effects on blood retrotransposable element expression levels: findings from the population-based Rhineland Study. *Aging Cell* **24**, e70092 (2025).
- Haugh, K. A. et al. The interferon-inducible antiviral protein DAXX is not essential for interferon-mediated protection against avian sarcoma virus. *Virology* **11**, 100 (2014).
- Yona, S. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* **38**, 79–91 (2013).
- Matejuk, A. & Ransohoff, R. M. Crosstalk between astrocytes and microglia: an overview. *Front. Immunol.* **11**, 1416 (2020).
- Paolicelli, R. C. et al. Synaptic pruning by microglia is necessary for normal brain development. *Science* **333**, 1456–1458 (2011).
- Monsorno, K. et al. Loss of microglial MCT4 leads to defective synaptic pruning and anxiety-like behavior in mice. *Nat. Commun.* **14**, 5749 (2023).
- Chen, D. et al. Microglia govern the extinction of acute stress-induced anxiety-like behaviors in male mice. *Nat. Commun.* **15**, 449 (2024).
- Liu, H. et al. TNF signaling pathway-mediated microglial activation in the PFC underlies acute paradoxical sleep deprivation-induced anxiety-like behaviors in mice. *Brain. Behav. Immun.* **100**, 254–266 (2022).
- Hammond, T. R. et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. *Immunity* **50**, 253–271 (2019).

46. Zhan, L. et al. A MAC2-positive progenitor-like microglial population is resistant to CSF1R inhibition in adult mouse brain. *eLife* **9**, e51796 (2020).
47. Marsh, S. E. et al. Dissection of artifactual and confounding glial signatures by single-cell sequencing of mouse and human brain. *Nat. Neurosci.* **25**, 306–316 (2022).
48. Byrns, C. N., Saikumar, J. & Bonini, N. M. Glial AP1 is activated with aging and accelerated by traumatic brain injury. *Nat. Aging* **1**, 585–597 (2021).
49. Holtman, I. R., Skola, D. & Glass, C. K. Transcriptional control of microglia phenotypes in health and disease. *J. Clin. Invest.* **127**, 3220–3229 (2017).
50. Fixsen, B. R. et al. SALL1 enforces microglia-specific DNA binding and function of SMADs to establish microglia identity. *Nat. Immunol.* **24**, 1188–1199 (2023).
51. Buttgerit, A. et al. SALL1 is a transcriptional regulator defining microglia identity and function. *Nat. Immunol.* **17**, 1397–1406 (2016).
52. Fasching, L. et al. TRIM28 represses transcription of endogenous retroviruses in neural progenitor cells. *Cell Rep.* **10**, 20–28 (2015).
53. Wei, K. et al. TRIM28 is an essential regulator of three-dimensional chromatin state underpinning CD8⁺ T cell activation. *Nat. Commun.* **16**, 750 (2025).
54. Nott, A. et al. Brain cell type-specific enhancer–promoter interactome maps and disease-risk association. *Science* **366**, 1134–1139 (2019).
55. Armache, A. et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. *Nature* **583**, 852–857 (2020).
56. Grubman, A. et al. Transcriptional signature in microglia associated with A β plaque phagocytosis. *Nat. Commun.* **12**, 3015 (2021).
57. Lallemand-Breitenbach, V. & de Thé, H. PML nuclear bodies: from architecture to function. *Curr. Opin. Cell Biol.* **52**, 154–161 (2018).
58. Amodeo, V. et al. A PML/SLIT axis controls physiological cell migration and cancer invasion in the CNS. *Cell Rep.* **20**, 411–426 (2017).
59. Ferbeyre, G. et al. PML is induced by oncogenic Ras and promotes premature senescence. *Genes Dev.* **14**, 2015–2027 (2000).
60. Askew, K. et al. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. *Cell Rep.* **18**, 391–405 (2017).
61. Seoane, M., Costoya, J. A. & Arce, V. M. Uncoupling oncogene-induced senescence (OIS) and DNA damage response (DDR) triggered by DNA hyper-replication: lessons from primary mouse embryo astrocytes (MEA). *Sci. Rep.* **7**, 12991 (2017).
62. Zhang, X. et al. The loss of heterochromatin is associated with multiscale three-dimensional genome reorganization and aberrant transcription during cellular senescence. *Genome Res.* **31**, 1121–1135 (2021).
63. Schonhoff, A. M. et al. Border-associated macrophages mediate the neuroinflammatory response in an α -synuclein model of Parkinson disease. *Nat. Commun.* **14**, 3754 (2023).
64. Bancaro, N. et al. Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. *Cancer Cell* **41**, 602–619 (2023).
65. Wang, N. et al. Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity. *iScience* **27**, 110006 (2024).
66. Zhao, H. et al. Destabilizing heterochromatin by APOE mediates senescence. *Nat. Aging* **2**, 303–316 (2022).
67. Strom, N. I. et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. *Nat. Genet.* **58**, 275–288 (2026).
68. Yuan, P. et al. TREM2 haploinsufficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. *Neuron* **90**, 724–739 (2016).
69. Stratoulas, V. et al. ARG1-expressing microglia show a distinct molecular signature and modulate postnatal development and function of the mouse brain. *Nat. Neurosci.* **26**, 1008–1020 (2023).
70. Udayar, V., Chen, Y., Sidransky, E. & Jagasia, R. Lysosomal dysfunction in neurodegeneration: emerging concepts and methods. *Trends Neurosci.* **45**, 184–199 (2022).
71. Huang, L. et al. DAXX represents a new type of protein-folding enabler. *Nature* **597**, 132–137 (2021).
72. Georgiadou, P. et al. PML loss worsens NEK1-linked ALS and PML induction drives NEK1 degradation, precluding disease onset. *FEBS J.* <https://doi.org/10.1111/febs.70487> (2026).
73. Wang, Y. et al. PML targets and resolves structured protein inclusions to mitigate neurodegeneration. *Nat. Cell Biol.* **28**, 520–535 (2026).
74. Keren-Shaul, H. et al. A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* **169**, 1276–1290 (2017).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

Xin Yan^{1,2,27}✉, Christina Georgopoulou^{1,27}, Hang-Mao Lee^{1,27}, Ala Ahrari¹, Jenny Russ¹, Vijay Chandrasekar¹, Tim Ducksch¹, Giuliano Crispatsu¹, Valentina Talevi³, Liang Qiao^{4,5}, Shobhit Agrawal^{6,7}, Sophie Crux⁸, Andrew W. Daman⁹, Lena Wischhof¹⁰, Miriam Stork¹, Margit Zweyer¹, Emma Dorotea Zanfi¹, Manon Chevallot-Beroux¹, Yunxiao Li², Elena De-Domenico⁶, Dina Hüsön⁷, Lorenzo Bonaguro^{6,11}, Yuanfang Li⁷, Jonas Schulte-Schrepping^{6,11}, Qingyi Liang¹², Ketty Kessler¹², Dan Ehninger¹³, Shahin Rafii¹⁴, Jiankai Luo², Andreas Hermann^{2,15}, Annett Halle^{16,17}, Ying Liu^{14,18}, Elvira Mass¹⁹, Melania Capasso²⁰, Hiroki Kato²¹, Joachim L. Schultze^{6,11,22}, Pierluigi Nicotera²³, Daniele Bano¹⁰, Steven Zvi Josefowicz⁹, Martin Fuhrmann⁸, Thomas Ulas⁶, Marc Beyer^{6,7}, Juntang Lin^{4,5,24}, Monique M. B. Breteler^{3,25}, N. Ahmad Aziz^{3,25,26} & Paolo Salomoni^{1,12}✉

¹Nuclear Function Group, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. ²Translational Neurodegeneration Section 'Albrecht Kossel', University Medical Center Rostock, University of Rostock, Rostock, Germany. ³Population Health Sciences, DZNE and Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Bonn, Germany. ⁴Collaborative Innovation Center of Stem Cell and Biotherapy, Henan Medical University, Xinxiang, China. ⁵Henan Joint International Research Laboratory of Stem Cell Medicine, Henan Medical University, Xinxiang, China. ⁶Platform for Single Cell Genomics and Epigenomics (PRECISE), DZNE and University of Bonn, Bonn, Germany. ⁷Immunogenomic and Neurodegeneration Group, DZNE, Bonn, Germany. ⁸Neuroimmunology and Imaging Group, DZNE, Bonn, Germany. ⁹Immunology and Microbial Pathogenesis Program, Department of Pathology and Laboratory Medicine, Division of Cell and Cancer Pathobiology, Weill Cornell Medicine Graduate School of Medical Sciences, New York, NY, USA. ¹⁰Aging and Neurodegeneration Group, DZNE, Bonn, Germany. ¹¹Clinical Single Cell Omics, Systems Medicine, DZNE, Bonn, Germany. ¹²Department of Cancer Biology, University College London (UCL) Cancer Institute, University College London, London, UK. ¹³Translational Biogerontology Group, DZNE, Bonn, Germany. ¹⁴Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. ¹⁵German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, Rostock, Germany. ¹⁶Microglia and Neuroinflammation, DZNE, Bonn, Germany. ¹⁷Department of Neuropathology, University Hospital Bonn, Bonn, Germany. ¹⁸Department of Surgery, Weill Cornell Medicine, New York, NY, USA. ¹⁹Life and Medical Sciences (LIMES) Institute, Developmental Biology of the Immune System, University of Bonn, Bonn, Germany. ²⁰Immune Regulation Group, DZNE, Bonn, Germany. ²¹Institute of Cardiovascular Immunology, University Hospital Bonn, University of Bonn, Bonn, Germany. ²²Genomics and Immunoregulation, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany. ²³Synaptic Connectivity and Neurodegeneration Group, DZNE, Bonn, Germany. ²⁴Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China. ²⁵Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of Bonn, Bonn, Germany. ²⁶Department of Neurology, Faculty of Medicine, University of Bonn, Bonn, Germany. ²⁷These authors contributed equally: Xin Yan, Christina Georgopoulou, Hang-Mao Lee. ✉e-mail: xin.yan@dzne.de; paolo.salomoni@dzne.de

Methods

Measurements of *DAXX* and RTEs levels in humans

Study population. We used data from participants of the Rhineland Study, an on-going population-based cohort study in Bonn, Germany. Invitations to participate in the Rhineland Study are extended to all inhabitants of two geographically defined areas of Bonn who meet the inclusion criteria: aged 30 years and older and sufficient command of the German language to give informed consent. The mean (s.d.) age was 55.40 (14.48) years, and 45.4% were men (see Source Data Fig. 1). The study was approved by the ethics committee of the University of Bonn, Medical Faculty. The Rhineland Study is carried out in accordance with the recommendations of the International Conference on Harmonization Good Clinical Practice standards. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Whole-blood RNA isolation and sequencing. Total RNA was isolated from 3,480 peripheral blood samples. The blood was collected in PAXgene Blood RNA tubes (PreAnalytix/Qiagen) and processed in accordance with the manufacturer's instructions. Total RNA was extracted following the manufacturer's guidelines using a PAXgene Blood miRNA kit. The integrity and quantity of RNA were assessed using a TapeStation RNA assay on a 4200 TapeStation system (Agilent Technologies). We used 750 ng of total RNA to generate next-generation sequencing libraries using the TruSeq stranded total RNA kit (Illumina) following the manufacturer's instructions with Ribo-Zero Globin reduction. Library size distribution was assessed via D1000 ScreenTape assay on a TapeStation 4200 system (Agilent), and library quantification was performed using a Qubit HS dsDNA assay (Invitrogen). The libraries were clustered at a final concentration of 250 pM on a NovaSeq6000 instrument using NovaSeq S2 v1 chemistry (Illumina) in XP mode for the first batch of 3,000 samples and NovaSeq S4 v1.5 chemistry for the last batch of 480 samples. Paired-end sequencing with 2×50 cycles was conducted before demultiplexing using bcl2fastq2 v2.20. Quality control of the sequencing data was performed through FastQC (v0.11.9).

RTE subfamily and loci profiling. Expression levels of RTEs in the RNA-seq data were quantified using the Software for Quantifying Interspersed Repeat Elements (SQUIRE) pipeline⁷⁵. The sequencing reads were aligned to the hg38 human reference genome obtained from UCSC, and the RTEs were annotated using RepeatMasker. The SQUIRE pipeline generates read counts and fragments per kilobase transcript per million reads (FPKM) for RTE subfamilies. In our analysis, we included RTE subfamilies expressed in at least 5% of the participants with an average of mapped reads equal or greater than 15. FPKM counts were log transformed to conform the data to a normal distribution.

Gene expression profiling. We obtained gene expression levels in the RNA-seq data by aligning the sequencing reads to the GRCh38.p13 human reference genome provided by Ensembl using STAR v2.7.1. We obtained the count matrix through the STAR command `-quantMode GeneCounts` using the GRCh38.101 human gene annotation. Genes expressed in at least 5% of the participants and with an overall mean expression greater than 15 reads were included in the analysis. Last, we applied the varianceStabilizingTransformation function from DESeq2 v1.30.1 on the counts to normalize for library size and to log transform the data.

Demographic and biochemical variables. Age, sex and smoking status data were derived from self-reports. Smoking status was categorized as a binary variable (for example, current smoker and not-current smoker). We imputed missing smoking status values using cotinine metabolite levels, measured through the Metabolon HD4 platform⁷⁶. Differential blood cell counts were measured at the Central Laboratory of the University Hospital in Bonn using EDTA-whole-blood samples on a hematological analyzer Sysmex XN9000.

Statistical analysis. Before conducting statistical analyses, we standardized all continuous variables to enable comparisons among variables with different units of measurement. To assess the association between *DAXX* (main independent variable) and each RTE subfamily (dependent variable), we performed a multivariable regression analysis, while adjusting for age, sex, smoking status and batch effect (Model 1) and additionally for white and red blood cell counts (Model 2). The FDR method was used to correct for multiple comparisons, with the threshold for statistical significance set at $FDR < 0.05$. A sensitivity analysis was performed on a subset of the Rhineland Study population. This subset comprised participants with the lowest 20% of *DAXX* expression levels (low-*DAXX* group) and those with the highest 20% of *DAXX* expression levels (high-*DAXX* group). Subsequently, we assessed the association between *DAXX* groups and each RTE subfamily, while controlling for the same covariates as described above.

To interpret the biological role of *DAXX*, we first assessed its correlation with all genes available in the Rhineland Study dataset. Next, we conducted a rank-based gene set enrichment analysis, ranking the genes in descending order according to the Spearman's correlation of their expression levels with that of *DAXX*. Specifically, a GO analysis for the correlation of *DAXX* expression with the expression levels of 12,167 other genes measured in the Rhineland Study ($N = 2,966$) was performed. All genes were first ranked in descending order according to the Spearman's correlation of their expression levels with that of *DAXX*, followed by a rank-based gene set enrichment analysis, applying FDR correction to account for multiple comparisons (all *P* values are two-sided and based on a permutation test using a weighted Kolmogorov–Smirnov-like statistic⁷⁷, as implemented in the clusterProfiler R package v. 3.18.1).

Animals

All experimental procedures were approved by Landesamt für Verbraucherschutz und Ernährung Nordrhein-Westfalen (formerly Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen) under protocols 81-02.04.2016.A486, 81-02.04.2020.A346 and 81-02.04.2021.A019.

Mice were maintained on a 12-h light/12-h dark cycle with ad libitum access to regular chow food (ssniff Spezialdiäten). The following mice were used in this study. *Daxx*-floxed mice²⁷ were generated by Taconic Artemis. The targeting vector contained a neomycin (*NeoR*) gene surrounded by flippase sequences (*FRT*) and a puromycin (*PuroR*) gene surrounded by F3 sites, which were removed by in vivo Flp-mediated recombination. In the resulting strain, exons 2–7 of *Daxx* were flanked by *loxP* sequences. C57BL/6N floxed *Hira* mice (*Hira*^{fl/fl}) were provided by P. Adams (Sanford Burnham Prebys Medical Discovery Institute)⁷⁸. The brain sections of *Rosa26-Cre*^{ERT2}, *H3.3A*^{fl/fl}/*H3.3B*^{-/-} mice were provided by S. Rafii (Department of Medicine, Weill Cornell Medicine)⁷⁹. *Ifnar*-KO mice (028228), *Cx3cr1-Cre*^{ERT2} mice (021160), *Rosa26-Cre*^{ERT2} mice (008463), *Mx1-Cre* mice (003556) and APP/PS1 mice (034823) were purchased from The Jackson Laboratory. The following genotyping primers for the *Daxx*-floxed allele were used: 5'-AGATCCTGTCTCTCCTGTCTATCC-3' (*Daxx* forward) and 5'-CACTGGGTAGACTAGACTG-TGGC-3' (*Daxx* reverse). To check for recombination induced by Cre recombinase, we used the following primers: 5'-GGAGGGAGTCAAGAGTTGG-3' (*Daxx* forward), 5'-TGCGTTTCCTGTCTTTCGG-3' (*Daxx* reverse) and 5'-GCTCAGCCCTTAGTCCGAA-3' (*Daxx* recombined). To induce Cre activation, *Rosa26-Cre*^{ERT2}- or *Cx3cr1-Cre*^{ERT2}-positive mice were treated with 80 mg per kg (body weight) per day TAM (T5648, Sigma-Aldrich) via oral gavage for five consecutive days. Both sexes were tested and used in most experiments. Behavioral analyses were performed on 4- to 5-month-old male mice. The *n* values in the figure legends reflect the number of mice analyzed in each experiment.

Behavioral tests

Open field. To assess their exploratory and locomotor behavior, mice were placed in a lighted 25-cm-wide box with no escape for a single 10-min session. The box itself was divided into a central zone and a peripheral zone. The distance and/or the movement within the zones was recorded to calculate the fear versus exploratory behavior⁸⁰.

Elevated plus maze. To investigate anxiety- and fear-associated behavior⁸¹, the animals were placed for 5 min in the center of a cross-shaped maze composed of two open arms (no walls) and two closed arms (with walls). Their anxiety was triggered by the height of the 1-m-high platform, prompting the animals to seek protection in the closed arms. As a measure of this anxiety, the time spent in the closed arms was recorded.

Rotarod. To assess their motor coordination and balance, the mice were placed on an accelerating rotarod for 5 min, which increased in speed from 4 to 40 rpm over time. The test was repeated four times per day for 4 consecutive days. The duration of their stay on the rod was recorded⁸².

Barnes maze. Spatial learning and memory were tested using the Barnes maze test⁸³. Briefly, animals were trained to locate a 1-m-high circular platform with 20 equally sized holes along the perimeter. An escape platform (circle, 10 cm in diameter) was placed 1.0 cm below the water surface (hidden) in a pool 120 cm in diameter. Each mouse was placed in the center of the maze covered by a dark start box for 10 s. After 10 s, the mouse was allowed to freely explore the platform for a limited time period (90 to 180 s). The test consisted of three different phases: (1) habituation (the first day with one trial per mouse), (2) acquisition (5 consecutive days with two trials per mouse) and (3) probe test (on days 7 and 14 with one trial per mouse). During the habituation phase, the mouse could explore the platform for only 1 min and was then led to the escape hole, where it remained in the escape box for another 2 min. However, during the acquisition phase, the mouse had 3 min per trial to explore the maze and find the escape hole/box. In case of failure, the mouse was led again to the escape hole, where it remained for an additional 2 min. Last, the final probe tests were performed 24 h and 7 days after the last acquisition. During the probe tests, the escape hole was plugged, and the mouse was allowed to explore the maze for a total time period of 120 s. The latency to reach the plugged escape hole and the cumulative duration spent in the target area were measured for the 2 probe days.

Primary cell culture

For primary microglia culture, cortical hemispheres from newborn mice (P2) were cleared of meninges and homogenized in ice-cold DMEM supplemented with 20% FBS and 1% penicillin/streptomycin. After filtration through a 70- μ m cell strainer, the cell suspensions were centrifuged at 700g for 5 min, followed by resuspension. The cells were then plated in a poly-L-lysine-coated T25 flask and maintained in a 37 °C incubator with 5% CO₂. After 24 h, half of the culture medium was replaced with fresh medium supplemented with 10% L929 supernatant. The medium was changed every second day for 7–10 days, until the coculture of microglia and astrocytes had reached the desired confluence. The cultured microglia were detached from the astrocyte layer by 'shaking' the flask and were replated for further experiments.

For primary BMDM cultures, the hind legs of 3-month-old mice were collected. After separating the tibiae and femurs, the bone marrow was flushed through a 70- μ m cell strainer. In total, 1.4×10^6 cells were plated per 150-mm nontreated dish into DMEM (11960, Gibco) supplemented with 10% FBS, 1% penicillin/streptomycin, $1 \times$ GlutaMAX (35050061, Gibco) and 20% freshly added L929 supernatant. After 4 days in cell culture, half of the medium was replaced with fresh 10% supplemented medium. At day 6, the cells were detached using

cell dissociation buffer (13151-014, Gibco), counted and replated for further experiments.

To induce *Daxx* deletion in *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia or *Rosa26*-Cre^{ERT2}; *Daxx*^{fl/fl} BMDMs, the cultured cells were treated with 5 μ M 4-hydroxytamoxifen (SML1666-1ML, Sigma-Aldrich) for 24 h. The culture medium was then replaced with fresh medium, and the cells stayed in culture for a total period of 5 days to obtain a completed *Daxx* deletion.

NPCs were isolated from E13.5 mouse cortex. Cells were cultured in Neurobasal medium containing 10% supplement (proliferation), 1% penicillin/streptomycin, 10 ng ml⁻¹ epidermal growth factor and 10 ng ml⁻¹ fibroblast growth factor in a 37 °C incubator with 5% CO₂. To overexpress *Daxx* in NPCs, 150,000 cells per well were seeded in six-well plates with 2 ml of DMEM and incubated overnight at 37 °C. On the second day, the medium was replaced with fresh medium 1 h before transduction. The volume of the virus per well was calculated at a multiplicity of infection of 7 (volume = (multiplicity of infection $\times$ number of cells) / total). Empty vector (pHIV-dTomato) and Flag-DAXX (Flag-DAXX-pHIV-dTomato) lentiviruses were mixed into the medium and added to the cells for lentiviral transfection, followed by an 8-h incubation at 37 °C. After 8 h, the medium was replaced with fresh medium, and the cells were further incubated for another 48 h. Transduced NPCs were then prepared for fluorescence-activated cell sorting in a concentration of 10×10^6 cells per ml. The tdTomato⁺ cells were sorted and plated in 24-well plates and T25 flasks for further expansion. The expanded cells were subsequently used for immunohistology and immunoblotting assays.

ELISA

For the quantification of secreted proinflammatory cytokines (IFN β and TNF) in BMDM supernatants, ELISAs were performed using Mouse IFN- β DuoSet (DY8234, R&D Systems) and Mouse TNF ELISA Set II (558534, BD OptEIA) ELISA kits, according to the manufacturers' guidelines.

Microglia isolation from adult mouse brains

Microglia were isolated from adult mouse brains using the Adult Brain Dissociation kit from Miltenyi Biotec according to the manufacturer's instructions. In brief, after euthanasia, mouse brains were mechanically and enzymatically digested at 4 °C. Fully digested tissue suspensions were filtered with a 70- μ m cell strainer, followed by subsequent removal of myelin, cell debris and erythrocytes. The cell suspension was then incubated with CD11b MicroBeads (Miltenyi Biotec) for 15 min at 4 °C, followed by a separation in MS columns (Miltenyi Biotec) using a magnetic field on a MACS MultiStand and QuadroMACS (Miltenyi Biotec). The isolated microglia were collected for further experiments, such as protein extraction or RNA isolation.

Immunohistochemistry and image analysis

Brains were collected from mice and fixed overnight in 4% paraformaldehyde in 0.1 M PBS. The fixed brains were placed in a mixture of 20% glycerol and 2% dimethyl sulfoxide in 0.4 M PBS for 24 h for cryoprotection. Brain sections (40 μ m) were collected in 0.1 M PBS. Primary mouse or rat monoclonal, rabbit, guinea pig or chicken polyclonal antibodies to ApoE (ab183597, Abcam), bassoon (ADI-VAM-PS003-F, Enzo), CD68 (137001, Biolegend), cleaved caspase-3 (9661, Cell Signaling), DAXX (sc-7152, Santa Cruz), GFAP (ab4674, Abcam), γ H2AX (9718, Cell Signaling), Homer1 (160006, Synaptic Systems), IBA1 (234004, Synaptic Systems), Ki67 (ab16667, Abcam), LAMP1 (ab25245, Abcam), MBP (ab7349, Abcam), NeuN (ab134014, Abcam), SMI31 (801602, Biolegend) and SOX9 (ab185230, Abcam) were used. Sections were washed three times in PBS (3 $\times$ 15 min each), followed by washing several times in PBS containing 0.3% Triton X-100 (9 $\times$ 20 min each). Sections were preincubated with PBS containing 5% normal goat serum and 0.3% Triton X-100 for 1 h to block nonspecific binding and subsequently incubated with primary antibody at 4 °C for 48 h. Sections were then washed nine

times for 20 min each in 0.3% Triton X-100 in 0.1 M PBS and incubated with Alexa-conjugated secondary antibodies (1:500) for 2 h using standard techniques. Finally, sections were mounted on gelatin-coated glass slides and coverslipped in Immu-Mount. Co-staining of SA- β -Gal activity and IBA1 protein in brain sections was performed by staining for SA- β -Gal first using the Senescence β -Galactosidase Staining kit (9860, Cell Signaling). Subsequently, sections were processed for immunofluorescence staining as described previously. Fluorescence was imaged under a confocal microscope (Zeiss, LSM900). Digital images were analyzed with Fiji/ImageJ.

For microglial morphology analysis, fluorescence emission sections were scanned at a resolution of $1,024 \times 1,024$ pixels with 8-bit sampling in sequential scanning frame-by-frame mode using a $\times 20$ Plan-Apochromat objective. Analysis of microglial morphology was performed using the ImageJ MotiQ plugin, as previously described^{84,85}. For high-resolution three-dimensional analysis, samples were scanned using a Plan-Apochromat $\times 63/1.32$ -NA oil DIC objective at a resolution of $1,024 \times 1,024$ pixels with 8-bit sampling in sequential scanning frame-by-frame mode. Single optical sections were acquired using identical acquisition settings, with a pinhole of 1 Airy unit. Stacks of 20–29 optical sections yielded voxel dimensions between 100 and 400 nm for the x , y and z planes. Three-dimensional reconstructions were generated with Imaris v9.8 software (BitPlane, Oxford Instruments).

Western blotting

Total protein from brain tissue or microglia was lysed with freshly prepared modified RIPA buffer (50 mM Tris pH 8, 0.5 mM EDTA, 150 mM NaCl, 0.5% SDS, 1% Triton X-100). The lysates were quantitated using a Pierce BCA Protein Assay kit (23225, Thermo Fisher Scientific). Equal amounts of protein (10–30 μ g) were separated by SDS-PAGE electrophoresis, transferred to a PVDF membrane and blocked in 2.5% skim milk in Tris-buffered saline with Tween-20 (TBST). Membranes were then incubated overnight with primary antibody solution at 4 °C followed by a 2-h incubation with secondary antibody at room temperature. Proteins were detected using the Odyssey Infrared Imaging System (LI-COR Biosciences). The following primary and secondary antibodies were used in this study: ApoE (ab183597, Abcam), β -actin (A5541, Sigma-Aldrich), CD68 (137001, Biolegend), DAXX (sc-7152, Santa Cruz), DAXX (ab32140, Abcam), GAPDH (ab8245, Abcam), GFAP (ab4674, Abcam), H2AX (2595, Cell Signaling), γ H2AX (9718, Cell Signaling), H3.3 (09-898, Millipore), TRIM28 (ab10484, Abcam), MDA5 (PA5-20337, Thermo Fisher), MBP (ab7349, Abcam), p53 (NCL-L-P53-CM5P, Leica Biosystems), p-p53 (9284, Cell Signaling), PML (05-718, Millipore), STAT1 (9172S, Cell Signaling), p-STAT1 (9167S, Cell Signaling), synaptophysin (4329, Cell Signaling) and Alexa Fluor 680- or IRDye 800-labeled goat anti-rabbit, mouse, rat and chicken IgG antibodies. GAPDH or β -actin was used as a loading control. Blots were quantified using ImageJ (National Institutes of Health, <https://imagej.nih.gov/ij/>).

RNA extraction and gene expression analysis

Total RNA was extracted from brain-isolated cells or primary cultured cells using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. RNA concentration was quantified using an ND1000 Spectrophotometer (NanoDrop), followed by reverse transcription using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative real-time PCR was performed on a 7500 Fast Real-Time PCR system (Applied Biosystems) using Fast SYBR Green Master Mix (Applied Biosystems). Relative abundance of the specific transcripts was normalized to *Gapdh* mRNA and calculated using the $2^{-\Delta\Delta C_t}$ method. The housekeeping gene *Gapdh* was used as an internal control for mRNA expression. The following primer sequences were used: 5'-GATGACTATAGGCCAGGCGT-3' (*Daxx* forward), 5'-TCGTCTCTTCTGTCTCTCGC-3' (*Daxx* reverse), 5'-CTCCACTCACGGCAAATTCAA-3' (*Gapdh* forward), 5'-GATGACAAGCTTCCCATTCG-3' (*Gapdh* reverse), 5'-ACAGATCAGCTCGAGTGCAAA-3' (*ApoE*

forward), 5'-ATCTTGCGCAGGTGTGTGGAGA-3' (*ApoE* reverse), 5'-CCTGGTGATGCCGACCTG-3' (*Cdkn1a* forward) and 5'-CCATGAGCCCATCGCAATC-3' (*Cdkn1a* reverse).

Bulk RNA-seq data processing and analysis

Bulk RNA-seq library preparation. For RNA-seq, the extracted RNA was resuspended in RNase-free water, and RNA quantity and quality (RINe) were assessed via the HS RNA analysis ScreenTape assay on a 4200 TapeStation system (Agilent Technologies). Libraries were prepared using the SMARTer Stranded Total RNA-Seq Kit v3 according to the manufacturer's instructions (Takara Bio). Briefly, total RNA was reverse transcribed into cDNA using N6 random primers, and adapters for Illumina sequencing were added through PCR via a limited-cycle PCR program. The PCR products were purified using AMPure XP beads and further amplified via a limited-cycle PCR program to generate multiplexed sequencing libraries. Library concentration was measured using the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific), and size distribution was assessed using the HS D5000 ScreenTape assay on a 4200 TapeStation system (Agilent Technologies). Libraries were sequenced on an Illumina NextSeq 500 or Illumina NovaSeq 6000 according to the manufacturer's instructions.

RNA-seq analysis. For coding genes, FASTQ files were adaptor trimmed using TrimGalore with default parameters, aligned to genome build mm10 by STAR, filtered by mapq > 10 using SAMtools and deduplicated using Picard (<https://broadinstitute.github.io/picard/>). A count matrix was assembled using featureCounts. DESeq2 was then used to perform rlog/vst transformation, generate PCA plots, acquire the normalized counts and identify differentially expressed genes.

For repetitive elements, SQUIRE⁷⁵ was used to handle genome alignment, count matrix generation and identify differentially expressed repetitive elements. Subfamily counts from all samples were assembled, rounded to integers and supplied to DESeq2 for normalization. The adjusted P values from DESeq2 were used for volcano plots and selection of differentially expressed genes.

Clustering of RTE subfamily expression in GSE79819. Normalized subfamily counts were averaged across replicates, $\log_2$ transformed and split into two tables for LTRs and non-LTRs. Subfamily expression in each table was z -score transformed across samples, and subfamilies containing any 'NA' values were removed before clustering using the KMeans method from the sklearn Python package.

Clustering of RTE subfamily expression in GSE208386. Samples from both sexes were selected. RTE analysis and normalization followed the same procedures as described earlier. Subfamilies were filtered out if their normalized expression had a value of 0 in more than half of the total samples. Normalized subfamily counts were averaged across replicates without distinction of sex. The averaged counts were $\log_2$ transformed, split into two tables for LTRs and non-LTRs, z -score transformed across all ages and clustered by k -means = 5 using the sklearn package.

Selection of RTE copies that responded to LPS treatment at 6 h then subsided at later time points. Differentially expressed RTE copies in wild-type mice after LPS treatment were obtained using the following comparison settings: (1) LPS 6 h versus untreated (Comp. A), (2) LPS 24 h versus untreated (Comp. B) and (3) LPS 48 h versus untreated (Comp. C). A preselected set of RTE copies was identified as any RTE copy having an adjusted P value of <0.05 in at least one comparison among Comp. A, Comp. B or Comp. C. The preselected RTE copies were further filtered by ($\log_2$ (fold change) Comp. A > 0) AND ($\log_2$ (fold change) Comp. B < $\log_2$ (fold change) Comp. A) AND ($\log_2$ (fold change) Comp. C < $\log_2$ (fold change) Comp. B) to get the targeted RTE copies.

Heat map of RTE expression in LPS-treated ex vivo dataset. Locus-specific RTE counts for LPS-treated ex vivo wild-type and *Daxx*-KO samples were normalized using the same procedure applied for subfamily counts. The normalized transposable element counts for targeted RTE copies were extracted, averaged across replicates, z-score transformed, split into two tables for LTRs and non-LTRs and clustered using the KMeans method from the sklearn package. Clusters of RTE copies that did not show reduced expression at 24 h compared to 6 h in *Daxx*-KO mice were extracted, and their loci were supplied to GREAT (<http://great.stanford.edu/>) for GO analysis using default settings.

Analysis of neighboring genes for the top 30 overexpressed intergenic LTRs in ex vivo LPS treatment. Locus-specific differential RTE expression from SQUIRE was filtered to keep intergenic LTRs. Intergenic LTRs were identified by the locus not overlapping with known genomic regions (downloaded by Table Browser from the UCSC Genome Browser), which included upstream 5-kb and downstream 1-kb extensions. The intergenic locus-specific SQUIRE results in each comparison were first filtered by an adjusted *P* value of <0.05, and the loci in the top 30 log₂ (fold change) were collected from each comparison. The top 30 loci from each comparison were pooled, and their neighboring genes were obtained by using the annotatePeakInBatch function from the ChIPpeakAnno package with maxgap = 20,000. The log₂ (fold change) and adjusted *P* values for the neighboring genes in the *Daxx*-KO versus control DESeq2 results were retrieved for PBS and 6-, 24- and 48-h LPS treatment. A heat map was produced by color coding log₂ (fold change) and printing the adjusted *P* value inside the grid.

Clustering of locus-specific RTEs in in vivo samples. Differentially expressed RTEs between *Cx3cr1*-Cre^{ERT2}; *Daxx*^{WT/WT} and *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at various time points were selected by an adjusted *P* value of <0.1 and pooled. Unique RTEs were identified from the pooled set, and the log₂ (fold change) values from various time points were assembled for the unique RTEs. The assembled log₂ (fold change) table was split according to LTRs and non-LTRs. Each table for LTRs/non-LTRs was clustered using a Gaussian mixture model from the sklearn library into five clusters.

Statistical analysis of overlaps among peak sets or gene sets. The R package SuperExactTest⁸⁶ was used to calculate the significance of overlapping among multiple gene sets, and the fisher function from bedtools was used for overlapping between two peak sets.

ATAC-seq data processing and analysis

ATAC-seq library preparation. For ATAC-seq, approximately 50,000 to 100,000 isolated microglia were processed immediately for library construction. The cells were spun down at 500g for 5 min and washed with cold PBS. Thereafter, cells were resuspended into a mix of nuclease-free water, 1% digitonin and 10% Tween-20, mixed by vortexing and spun down briefly. The tagmentation reaction was performed by adding Nextera's Tn5 Transposase (TDE1) in the reaction buffer. The transposition reaction mix was incubated for 30 min at 37 °C, followed by DNA purification using a MinElute PCR purification kit (Qiagen). ATAC-seq libraries were generated from the tagmented DNA by PCR amplification using Nextera index primers (Illumina) according to the manufacturer's instructions. ATAC-seq libraries were then purified using a PCR purification MinElute kit (Qiagen) and quantified using KAPA library quantification kits (Kapa Biosystems) and a D1000 ScreenTape assay on a TapeStation 4200 system (Agilent). Libraries were sequenced on an Illumina NovaSeq 6000 according to the manufacturer's instructions.

ATAC-seq analysis. The FASTQ files were directly submitted to the atacseq pipeline (version 1.2.2) from nf-core (<https://github.com/nf-core/atacseq>) with arguments '-genome GRCm38', '-keep_multi_map' and '-min_reps_consensus 2'.

Motif search over DARs and overlap with microglia developmental enhancers. DARs were defined as an adjusted *P* value of <0.05 or <0.1 in some situations, which were later split into increased/decreased accessible regions according to log₂ (fold change) and annotated using the 'annotatePeak' function from the ChIPseeker R package with 'TxDb = TxDb.Mmusculus.UCSC.mm10.knownGene' and 'tss-Region = c(-3000,3000)'. DARs were defined as being intergenic if ChIPseeker annotated it as 'Distal Intergenic' and being nonintergenic otherwise. Motif search using findMotifsGenome.pl from HOMER was performed on DARs with feature combinations between (open; close) and (intergenic; nonintergenic; intergenic and nonintergenic combined). The *P* values from HOMER 'knownResults' files were used in heat map plotting.

Loci of LTRs in RepeatMasker data were downloaded from Table Browser on the UCSC Genome Browser. LTRs that overlapped with intergenic DARs were supplied to 'findMotifsGenome.pl' from HOMER for motif discovery. LTR loci overlapping with intergenic open regions were supplied to GREAT for GO analysis with default settings.

To calculate the significance of overlapping between differentially increased/decreased accessibility and microglia developmental enhancers, the differentially increased/decreased accessibility regions (adjusted *P* < 0.05) from *Cx3cr1*-Cre^{ERT2}; *Daxx*^{fl/fl} microglia at 3 d.p.i. were used as input to the 'bedtools fisher' command together with mouse microglia developmental enhancer regions identified in Matcovitch-Natan et al.³⁰.

CUT&Tag data processing and analysis

CUT&Tag library preparation. CUT&Tag for H3K9me3 was performed according to previously described protocols^{87,88}. In brief, around 50,000 nuclei per reaction were extracted from isolated microglia using NE1 buffer and incubated with activated Concanavalin A beads. Beads were then incubated with anti-H3K9me3 (Active Motif 39062, 1:50 dilution) at 4 °C overnight, followed by incubation with secondary antibody for 60 min. The transposase reaction was performed with pA(G)-Tn5 (1:20 dilution) in 300-wash buffer for 60 min at room temperature. Tagmentation was performed for 1 h in 300-wash buffer supplemented with 10 mM MgCl₂ in a 50-μl volume. After tagmentation, the beads were washed in 50 μl of TAPS buffer and resuspended in 5 μl of SDS release buffer for 60 min at 58 °C. Transposed DNA fragments were amplified using NEBNext High-Fidelity PCR Master Mix (New England Biolabs) and dual-indexed primers from IDT for Illumina Nextera DNA UD Indexes Set A (Illumina). Gap filling and 14 cycles of PCR were performed, followed by clean-up with 65 μl of SPRIselect beads (Beckman Coulter).

CUT&Tag for H3.3 was performed using an Active Motif CUT&Tag-IT Assay kit (53160, Active Motif). Briefly, 150,000–200,000 isolated microglia per reaction were bound to activated Concanavalin A beads. After successive incubations with H3.3 (Millipore 09-898, 1:20, overnight at 4 °C) and secondary (60 min) antibodies in Dig-wash buffer, the beads were washed and resuspended in pA-Tn5 transposomes (1:100 dilution) in Dig-300 buffer for 60 min at room temperature. The samples were then incubated in Tagmentation buffer for 60 min at 37 °C. After tagmentation, DNA fragments were further extracted and purified using a DNA purification kit. Subsequently, PCR amplification was performed using i7 and i5 primers for 14 cycles, followed by clean-up with 65 μl of SPRIselect beads (Beckman Coulter).

Quality check and measurement of the CUT&Tag libraries were performed using an HS D1000 DNA assay on a 4200 TapeStation system (Agilent Technologies). Libraries were sequenced as paired-end 2 × 75 bp reads on a NovaSeq X Plus system (Illumina). The experiments were run in duplicate or triplicate.

Data preprocessing. CUT&Tag reads were aligned using Bowtie2 (v2.2.1)⁸⁹ to the GRCm39/mm39 (or mm10 for the cluster analysis in Fig. 5a,b) reference genome with settings '--local --very-sensitive-local

--no-unal --no-mixed --no-discordant --phred33 -l10 -X 700'. BAM files were then created and sorted using SAMtools (v1.11)⁹⁰, before removing PCR duplicates using Picard (v2.20.4; <http://broadinstitute.github.io/picard/>) subroutine MarkDuplicates. ATAC-seq reads were aligned using BWA-MEM (v0.7.8-r455)⁹¹ to the GRCm39/mm39 reference genome with default settings. BAM files were then created and sorted using SAMtools (v1.11) before removing PCR duplicates using Picard (v2.20.4) subroutine MarkDuplicates. Merged samples were created using the SAMtools (v1.11) subroutine merge. Heat maps and profiles were plotted using deepTools (v3.5.3). Transposable element coordinates were extracted from the UCSC mm39 RepeatMasker (rmsk) file.

Differential binding. Human microglia-specific enhancers and promoters were extracted from Nott et al.⁵⁴. The coordinates were first converted to the mm10 genome and subsequently to the mm39 genome using UCSC-tools liftOver with a minimum 50% sequence identity. Binding changes were assessed using DiffBind (<http://bioconductor.org/packages/release/bioc/html/DiffBind.html>) with FDR < 0.05. While for microglia-specific enhancers, strict settings were applied (bUseSummarizeOverlaps = TRUE; plotMA_bUsePval = FALSE), for IAP elements, more lenient settings were used (bUseSummarizeOverlaps = FALSE, plotMA_bUsePval = TRUE).

H3.3⁺ subclustering. Profile plots of LTR subfamilies were assessed to obtain potential subclusters of H3.3⁺ sites following *Daxx* loss. To deduct the small set of binding sites that exhibit higher H3.3 binding in *Cx3cr1-Cre*^{ERT2}; *Daxx*^{fl/fl} microglia, we used the *k*-means clustering approach (nondeterministic; no seed) implemented in deepTools (v3.5.3). For the IAP and 'LTR (rest)' subfamilies, we initialized with increasing cluster sizes of 4, 6 and then 8 to observe whether the pattern remained/narrowed down candidates far enough. For *k*-means = 8, we obtained the clusters 8 (*n* = 10,821; 36.06%) for IAP and 7 (*n* = 2,293; 15.00%) for 'LTR (rest)'.

Motif search. Enriched de novo motifs were screened with HOMER (v5.1)⁹² using findMotifsGenome.pl with default settings ('-size 200 -mask') and the following input peaks: IAP-TSS peaks that were found to be more differentially bound in wild-type microglia than in *Cx3cr1-Cre*^{ERT2}; *Daxx*^{fl/fl} microglia (using DiffBind; *P* < 0.05; fold change > 0).

LTR proximity analysis. To assess the statistical significance of deregulated LTRs (belonging to ERV1, ERVK, ERVL, ERVL-MaLR, the IAP subgroup or the 'LTR (rest)' subgroup) within a specified range (<50 kb) of gene TSSs, we randomly selected 50 unique gene names associated with a TSS (Ensembl GRCm39.v114) using the UNIX function shuf and repeated this 100 times. The resulting mean value of enriched TSSs was used in a contingency table for Fisher tests. For enrichment analysis, we compared it to a preselected 'Cell cycle' gene list for strongly deregulated LTRs within 50 kb. We also used the human cell cycle KEGG pathway hsa04110 (accessed 2 October 2025; *n* = 158 genes, 154 mouse homologs) using the same approach.

scRNA-seq data processing and analysis

BD Rhapsody pipeline to prepare scRNA-seq libraries. Isolated microglia were labeled with unique oligonucleotide sample barcodes conjugated to antibodies to mouse CD45 (BD Mouse Immune Single-Cell Multiplexing kit, 633793), pooled in equivalent amounts and loaded on a BD Rhapsody cartridge (BD Bioscience, 400000847) using a BD Rhapsody Express Single-Cell Analysis System. Cell counting was performed using a Countess 3 FL automated cell counter (Invitrogen). Pooled samples were diluted using BD Sample Buffer to a final volume of 650 µl. Approximately 60,000 cells in total were loaded on a BD Rhapsody cartridge. Cell and bead loading, cell lysis, recovery of mRNA-bound beads, reverse transcription and exonuclease treatment

were performed according to the manufacturer's instructions (BD Biosciences). Whole-transcriptome library preparation, based on the random-priming strategy, and index PCR steps were performed using the BD Rhapsody mRNA Whole Transcriptome Analysis and Sample Tag Library Preparation Protocol, as per the manufacturer's instructions (BD Biosciences), optimized based on ref. 93. Quantification of the final libraries was performed using a Qubit Fluorometer with the Qubit dsDNA HS kit (Thermo Fisher Scientific), whereas the size distribution was assessed using the Agilent High-Sensitivity D5000 assay on a TapeStation 4200 system (Agilent Technologies). Paired-end sequencing (2 × 75 bp reads) was performed on a NovaSeq 6000 System (Illumina) using NovaSeq S1 Reagent Kit (200 Cycles) chemistry.

Preprocessing, quality assessment and control of single-cell transcriptome data. Raw bcl files were demultiplexed using Bcl2fastq V2.20 from Illumina, and the resulting paired-end scRNA-seq reads were filtered after quality control and matching cell barcodes with the barcode whitelist provided by BD. Subsequently, adaptors were trimmed using Cutadapt 1.16, and reads with a PHRED score of ≥20 were retained⁹⁴. Filtered reads were aligned using STAR 2.6.1b⁹⁵ to a customized genome that contained both the reference genome (mm10, Gencode: GRCm38.p6) and multiplexing tag sequences for aligning the transcriptome read and the sample barcode (hashtag oligonucleotide (HTO)). Quantification of gene expression and unique molecular identifier (UMI) count data matrix generation were performed using the Drop-seq-tools 2.0.0 pipeline (<https://github.com/broadinstitute/Drop-seq/>). Cells were assigned to the sample of origin by following the HTO-demultiplexing workflow of Seurat4 (refs. 96,97).

Normalization, cell clustering and cell filtering. In contrast to the Chromium 10x system, which uses water-in-oil droplets, the BD Rhapsody system applied here uses microfluidic chips consisting of micro-wells to create a plate array where cells can be captured and lysed in the presence of beads coated in oligonucleotides containing a poly(T) region, cell-specific barcodes, UMIs and unique sequence regions that facilitate molecular amplification. This results in lower doublet rates at the same cell capture number⁹⁸.

Our analysis implemented robust doublet correction through a dual approach. First, the BD Rhapsody system includes imaging quality control during the capture process, which directly identifies potential doublets at the hardware level. Second, we used molecular-based doublet detection using sample-specific HTOs. Specifically, we used the HTODemux function with a stringent positive.quantile threshold of 0.9999 to classify cells as singlets, doublets or negatives based on HTO enrichment patterns. This approach resulted in the identification and removal of doublets from our dataset, leaving only high-confidence singlets for downstream analysis. Additionally, standard quality control metrics were applied, removing cells with fewer than 250 genes or more than 500 UMIs per cell and cells with high mitochondrial content, further ensuring the exclusion of low-quality cells and potential technical artifacts. This comprehensive approach to doublet identification is more direct and reliable than computational inference methods used in non-tagged single-cell systems.

scRNA-seq data were analyzed in R (4.1.1) using Seurat v4 (ref. 96). The scRNA-seq data matrix was normalized using the NormalizeData function, followed by identification of the top 2,000 most variable features (genes) using the vst method in the FindVariableFeatures function. All genes were scaled and centered using the ScaleData function. PCA was performed on this centered expression matrix. The top 15 principal components (PC) were used to build a shared nearest neighbor cell graph, which was then clustered using the Louvain algorithm (resolution = 0.8) implemented in the FindClusters function. The PCs were then mapped onto two dimensions using the UMAP algorithm. Marker genes from Gerrits et al. were used to manually assign cell-type annotations to each cluster⁹⁹. Clusters not assigned as microglia or

macrophage, including a mixed cluster, were removed from further analysis. In addition, cells in clusters with a 'microglia' annotation were removed if they expressed high levels of *Ccr2* and *Ly6c2*. Finally, the DecontX function of the Bioconductor package celda (1.10.0) was used to estimate and remove contamination with ambient RNA. The resulting decontaminated count matrix was used to rerun normalization, feature selection, PCA, UMAP and clustering as described above.

Gene signatures for homeostatic, DAM-like, IFN, MHC and proliferating microglia were obtained from Chen and Colonna¹⁰⁰. Additional gene signatures for microglia subtypes were obtained from Hammond et al.⁴⁵. Gene signature enrichment scores were calculated and added to the Seurat v4 object using the AddModuleScore function.

Trajectories of microglia cells were reconstructed separately for wild-type and DAXX-deficient samples using monocle3 (1.0.0) and its learn graph function with use partition = F. Ordering of cells along pseudotime was done in a semisupervised manner by rooting the trajectory in the cluster where the majority of wild-type cells from the 3-d.p.i. time point fell (C0) or the majority of the DAXX-deficient cells from the 3-d.p.i. time point (C5).

Aging/repopulation data sets. The processed scRNA-seq data from Li et al.³³ and Zhan et al.⁴⁶ were downloaded from GEO (GSE207932 and GSE150169) and respectively merged using Seurat v5.1.0 (ref. 101) in R-4.2.1. Cells were slightly filtered for outliers keeping only those with nFeature_RNA > 500, nCount_RNA < 25,000, percent.mt < 20, nFeature_RNA > 500, nCount_RNA < 20,000 and percent.mt < 10, respectively. Data were then log normalized (scale.factor = 10,000) and scaled, and a PCA was conducted. For clustering, only the first 15 PCA dimensions (according to the Elbow plot) were used. Age-associated markers were calculated using the FindMarkers function with default settings and with the F24 versus F03 (one sample with LPS and PBS each) comparison. Repopulation markers were calculated in same manner in comparisons as indicated in Fig. 7e,f.

Statistical analysis

All statistical analyses were performed using Prism10 software (GraphPad Software). The numbers of experimental replicates and statistical tests used are indicated in the figure legends. The datasets met the assumptions of the statistical tests used. Sample allocation was random, and mice for experiments were randomly chosen based on availability of the right genotypes. All results are presented as mean ± s.e.m. A *P* value of less than or equal to 0.05 was considered statistically significant. Statistical significance is denoted as follows: **P* < 0.05, ***P* < 0.01 and ****P* < 0.001.

During animal studies, mice were labeled by animal identification number, and the experimenter was blinded to genotype during testing. For in vitro studies, genotypes were known to the experimenter due to the limited number of biological replicates. All other analyses were conducted with investigators blinded to the experimental condition.

Sample sizes for behavioral experiments were determined based on the current standard, as the minimum number of mice required to detect significance with an α rate set at 0.05 in a standard powered experiment. No statistical methods were used to predetermine sample sizes for other samples, but our sample sizes are similar to those reported in previous publication²⁷. No animals and data points were excluded from the analysis. Data distribution was assumed to be normal, but this was not formally tested.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Previously reported data were downloaded from Gene Expression Omnibus and online public resources. Hammond et al.⁴⁵ (GSE121654),

Li et al.³³ (GSE298386, GSE207932), Matcovitch-Natan³⁰ (GSE79819), Zhang et al.³⁴ (GSE52564), Buttgeriet et al.⁵¹ (E-MTAB-5077), Fixsen et al.⁵⁰ (GSE226092), Gerber et al.²⁷ (GSE119309) and Zhan et al.⁴⁶ (GSE150169). Data generated by this study are accessible at GSE255329, GSE267028, GSE276607, GSE272828 and GSE309782. The Rhineland Study's dataset is not publicly available because of data protection regulations. Access to data can be provided to scientists in accordance with the Rhineland Study's Data Use and Access Policy. Requests for further information or to access the Rhineland Study's dataset should be directed to rs-duac@dzne.de. Source data are provided with this paper.

Code availability

No custom software code was used in the data analysis for this paper.

References

- Yang, W. R., Ardeljan, D., Pacyna, C. N., Payer, L. M. & Burns, K. H. SQuIRE reveals locus-specific regulation of interspersed repeat expression. *Nucleic Acids Res.* **47**, e27 (2019).
- St. Helen, G. et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. *Cancer Epidemiol. Biomark. Prev.* **21**, 1105–1114 (2012).
- Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
- Rai, T. S. et al. HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia. *Genes Dev.* **28**, 2712–2725 (2014).
- Guo, P. et al. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. *Nat. Cell Biol.* **24**, 99–111 (2022).
- Walsh, R. N. & Cummins, R. A. The open-field test: a critical review. *Psychol. Bull.* **83**, 482–504 (1976).
- Pellow, S., Chopin, P., File, S. E. & Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. *J. Neurosci. Methods* **14**, 149–167 (1985).
- Jones, B. J. & Roberts, D. J. A rotarod suitable for quantitative measurements of motor incoordination in naive mice. *Naunyn. Schmiedebergs Arch. Exp. Pathol. Pharmacol.* **259**, 211 (1968).
- Gawel, K., Gibula, E., Marszalek-Grabska, M., Filarowska, J. & Kotlinska, J. H. Assessment of spatial learning and memory in the Barnes maze task in rodents-methodological consideration. *Naunyn. Schmiedebergs Arch. Pharmacol.* **392**, 1–18 (2019).
- Hansen, J. N. et al. MotiQ: an open-source toolbox to quantify the cell motility and morphology of microglia. *Mol. Biol. Cell* **33**, ar99 (2022).
- Plescher, M. et al. Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model. *Glia* **66**, 1464–1480 (2018).
- Wang, M., Zhao, Y. & Zhang, B. Efficient test and visualization of multi-set intersections. *Sci. Rep.* **5**, 16923 (2015).
- Henikoff, S., Henikoff, J. G., Kaya-Okur, H. S. & Ahmad, K. Efficient chromatin accessibility mapping in situ by nucleosome-tethered tagmentation. *eLife* **9**, e63274 (2020).
- Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. *Nat. Commun.* **10**, 1930 (2019).
- Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
- Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
- Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at <https://doi.org/10.48550/arXiv.1303.3997> (2013).

92. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime *cis*-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).
93. De Domenico, E. et al. Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. *STAR Protoc.* **1**, 100233 (2020).
94. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* <https://doi.org/10.14806/ej.171.200> (2011).
95. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
96. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 (2021).
97. Stuart, T. et al. Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902 (2019).
98. Li, W., Bazaz, S. R., Mayoh, C. & Salomon, R. Analytical workflows for single-cell multiomic data using the BD Rhapsody platform. *Curr. Protoc.* **4**, e963 (2024).
99. Gerrits, E. et al. Distinct amyloid- β and Tau-associated microglia profiles in Alzheimer's disease. *Acta Neuropathol.* **141**, 681–696 (2021).
100. Chen, Y. & Colonna, M. Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? *J. Exp. Med.* **218**, e20202717 (2021).
101. Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. *Nat. Biotechnol.* **42**, 293–304 (2024).

Acknowledgements

We would like to thank T. Sposito and other present and former members of the P.S. group, members of the laboratories of D.B. and M.C. and R. Behrendt (University of Bonn) for advice and discussion, R. Scholz (M.B. team) for CUT&Tag method sharing, J. Gruendemann and S. Krabbe (DZNE Bonn) for interpretation of behavioral studies, the Core Research Facilities and Services at DZNE and the DZNE Animal Research Facilities and Platform for Single Cell Genomics and Epigenomics (PRECISE) for their continuous support through the project, as well as all participants of the Rhineland Study and the study personnel involved in the extensive data collection. We also thank the group of D. Di Monte for support. P.S. was the recipient of an Honorary Professorship at University College London and was supported in part by the Hospitals Biomedical Research Centre and the Cancer Research UK University College London Experimental Cancer Medicine Centre.

Author contributions

P.S. conceived and designed the study and supervised the project. X.Y. and C.G. contributed to design of the study, performed in vivo and ex vivo experiments and analyzed data. X.Y. also contributed to study design, coordination and supervision of the project. H.-M.L. performed the bioinformatics analyses for bulk genomics and RTE expression and contributed to design of the study. A.A., J.R., V.C. and T.D. contributed equally to this work as second authors. J.R., S.A., E.D.-D., L.B. and J.S.-S. performed the single-cell analysis. G.C. performed ATAC-seq analysis, CUT&Tag analysis and single-cell analysis. A.A. and V.C. substantially contributed to the experimental work and data analysis, while V.C. also made the original observations at the core of the study. E.D.Z., T.D., Yunxiao Li, M.C.-B., A.W.D., L.W., L.Q., S.C., D.H. and Yuanfang Li contributed to experimental work. M.S. (while also on the team of D.B.), J.R. and V.C. contributed to obtaining animal experiment approvals from authorities and contributed to coordination of

animal work and animal colony management. Y. Liu contributed to animal work and sample preparation in Weill Cornell Medicine. C.G. performed behavioral tests with help from M.C.-B. V.T. processed and analyzed the data from human samples. X.Y., T.D., M.Z., Yunxiao Li, Q.L. and K.K. performed the experiments on NPCs. D.E., E.M., S.R., J. Luo, A. Hermann, A. Halle, M.C., H.K., J.L.S., P.N., D.B., S.Z.J., M.F., T.U., M.B., J. Lin, M.M.B.B., N.A.A. and P.S. contributed to personnel supervision, necessary study support and manuscript corrections. X.Y., C.G., H.-M.L., J.R. and P.S. wrote the manuscript. All authors read, edited and approved the manuscript.

Funding

P.S. is being and has been supported by the following funding bodies: the DZNE, the ERC (Consolidator Award H3.3Cancer, 616744), the Wilhelm Sander Stiftung, the Worldwide Cancer Research Fund, the Bonn Centre of Neuroscience, the Helmholtz-Gemeinschaft Aging and Metabolic Programming (AMPro) Consortium (to P.S., D.B. and D.H.) and the Ministry of Culture and Science of the State of Northrhine Westphalia (CANcer TARgeting, CANTAR programme as part of Netzwerke 2021 to P.S. and M.C., iBehave to M.F.). Further funding involved in this work is the Helmholtz-Gemeinschaft Innovation Pool, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC2151-390873048; DFG (YA721/3-1 to X.Y.; LU 1455/6-1 to J. Luo), DFG large-scale device funding (LSM900 Airyscan, INST 264/175-1 FUGG to A. Hermann), SFB 1454 432325352 (to E.M., J.L.S., M.M.B.B. and M.B.), FOR5547 project ID 503306912 (to E.M.), the European Research Council under the European Union's Horizon 2020 research and innovation program (851257 to E.M. and 865618 MicroSynCom to M.F.), the Federal Ministry of Education and Research grant (01KX2230; 'PreBeDem-Mit Prävention und Behandlung gegen Demenz'; to M.M.B.B.), the European Union's Horizon Europe research and innovation program under the MSCA Doctoral Networks 2021 (101072759 to M.C.), Marie Skłodowska-Curie Actions Individual Fellowship (892294 to J.R.), DFG under Priority Program SPP2395 (A. Halle, M.F. and S.C.) and the Natural Science Foundation of Henan province (252300421395 to L.Q.; 235101610002 to J. Lin). Open access funding provided by Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft.

Competing interests

The authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41593-026-02404-y>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41593-026-02404-y>.

Correspondence and requests for materials should be addressed to Xin Yan or Paolo Salomoni.

Peer review information *Nature Neuroscience* thanks Bing Ren and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.



Extended Data Fig. 1 | See next page for caption.


Extended Data Fig. 1 | Assessing correlation between Daxx and gene expression in human blood cells and its protein levels in an AD model. **a**, Gene ontology analysis for the correlation of *DAXX* expression with the expression levels of 12167 other genes measured in the Rhineland Study ($N = 2966$): all genes were first ranked in descending order according to the Spearman's correlation of their expression levels with that of *DAXX*, followed by a rank-based gene set enrichment analysis, applying false discovery rate (FDR) correction to account for multiple comparisons (P -values are two-sided and based on a permutation test using a weighted Kolmogorov-Smirnov-like statistic implemented in the clusterProfiler R package v. 3.18.1). **b-c**, Representative confocal images of Iba1 and 6E10 immunostaining and quantification of 6E10 intensity in the cortex of 12-month-old APP/PS mice ($n = 4$ mice) and wild type controls ($n = 3$ mice) (comparison by two-tailed unpaired Student's t test, $P_{6E10} = 0.005$,

$P_{\text{Pearson correlation}} = 0.0364$). **d, e**, Representative confocal images of Iba1 and Daxx immunostaining and quantification of Daxx intensity in the A β plaque⁺ and non-plaque-associated microglia from 12-month-old APP/PS mice ($n = 36$ and 13 cells, respectively, from 4 mice) and microglia from age-matched wild type controls ($n = 11$ cells from 3 mice) (Comparison by ordinary one-way ANOVA, $F = 5.462$, $P = 0.0068$; Sidak's multiple comparisons test, $P_{\text{plaque}^+ \text{ area vs WT}} = 0.0057$; $P_{\text{non-plaque area vs WT}} = 0.0491$). **f**, Western blots and quantification of Daxx and ApoE in microglia isolated from 12-month-old APP/PS1 mice and wild type controls ($n = 3$ mice per group, comparison by two-tailed unpaired Student's t test, $P_{\text{Daxx}} < 0.0001$, $P_{\text{ApoE}} = 0.0495$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 2 | Stimulation with LPS or Poly I:C increases Daxx expression in microglia and BMDMs *ex vivo*. **a, c**, Representative confocal images of Daxx and Iba1 immunostaining and quantification of Daxx intensity in primary microglia following PBS or 100 ng/mL LPS stimulation for 2 h, 24 h and 48 h ($n = 6$ independent preparations per group, comparison by ordinary one-way ANOVA, $F = 108.3$, $P < 0.0001$; Tukey's multiple comparisons test, $P_{\text{PBS vs LPS 2h}} < 0.0001$, $P_{\text{PBS vs LPS 24h}} < 0.0001$, $P_{\text{LPS 2h vs LPS 24h}} < 0.0001$, $P_{\text{LPS 24h vs LPS 48h}} = 0.0608$). **b, d**, Representative confocal images of Daxx and Iba1 immunostaining and quantification of Daxx protein intensity in primary cultured microglia upon PBS or 10 $\mu\text{g/mL}$ Poly I:C stimulation for 2 h, 24 h and 48 h ($n = 6$ independent preparations per group, comparison by ordinary one-way ANOVA, $F = 94.36$, $P < 0.0001$, Tukey's multiple comparisons test, P values: $P_{\text{PBS vs PolyI:C 2h}} = 0.9546$, $P_{\text{PBS vs PolyI:C 24h}} < 0.0001$, $P_{\text{PolyI:C 2h vs PolyI:C 24h}} < 0.0001$, $P_{\text{PolyI:C 24h vs PolyI:C 48h}} = 0.9937$). **e**, Volcano plots showing differentially expressed genes in primary microglia isolated from wild type mice following 2h-, 6h-, 24h- and 48h-LPS stimulation relative to PBS-treated controls. Differential expression analysis was performed using two-sided Wald tests implemented in DESeq2 with Benjamini–Hochberg


correction. Dotted lines indicate fold-change and adjusted P -value thresholds. **f**, Heatmap representing expression of RTE repressor and interferon-response genes in primary microglia after LPS stimulation. **g, h**, Western blots and quantification of Daxx, p-Stat1, Stat1 in BMDMs from *interferon alpha receptor* knockout (*IFNAR* KO) mice and control mice (*IFNAR* WT) following 6 h Poly I:C or LPS stimulation. PBS: $n = 4$ independent preparations for each genotype; Poly I:C: $n = 3$ independent preparations for *IFNAR* WT mice and $n = 4$ independent preparations for *IFNAR* KO mice; LPS: $n = 4$ independent preparations per group (Comparison by ordinary two-way ANOVA with Sidak's multiple comparisons test: for Daxx, $F = 4.449$, $P_{\text{PBS IFNAR WT vs IFNAR KO}} = 0.0919$, $P_{\text{PolyI:C IFNAR WT vs IFNAR KO}} < 0.0001$, $P_{\text{LPS IFNAR WT vs IFNAR KO}} = 0.0919$; for Stat1, $F = 8.321$, $P_{\text{PBS IFNAR WT vs IFNAR KO}} = 0.0009$, $P_{\text{PolyI:C IFNAR WT vs IFNAR KO}} < 0.0001$, $P_{\text{LPS IFNAR WT vs IFNAR KO}} < 0.0001$; for p-Stat1, $F = 2.279$, $P_{\text{PBS IFNAR WT vs IFNAR KO}} > 0.9999$, $P_{\text{PolyI:C IFNAR WT vs IFNAR KO}} = 0.0216$, $P_{\text{LPS IFNAR WT vs IFNAR KO}} = 0.0199$; for p-Stat1/Stat1, $F = 2.907$, $P_{\text{PBS IFNAR WT vs IFNAR KO}} > 0.9999$, $P_{\text{PolyI:C IFNAR WT vs IFNAR KO}} = 0.0072$, $P_{\text{LPS IFNAR WT vs IFNAR KO}} = 0.0174$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 3 | See next page for caption.

Extended Data Fig. 3 | Genetic deletion of *Daxx* results in Stat1 induction and cytokine secretion in primary microglia and BMDMs. **a**, Genotyping and immunoblot in primary microglia from *Cx3cr1-Cre^{ERT2};Daxx^{wt/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* ($n = 3$ mice per genotype). Arrows indicate the wild-type (226 bp), floxed (350 bp) and recombined (600 bp) alleles. Day0 protein levels were quantified by western blots (Comparison by two-tailed unpaired Student's t test, $P = 0.0056$). **b**, Volcano plot showing differentially expressed genes in *Daxx*-deficient versus control primary microglia following 6 h or 24 h LPS stimulation. Differential expression analysis was assessed using two-sided Wald tests implemented in DESeq2, P values were adjusted for multiple testing using Benjamini–Hochberg correction. **c**, Genotyping PCR confirming *ex vivo* *Daxx* recombination in *Rosa-Cre^{ERT2};Daxx^{flox/flox}* BMDMs following 24 h 4'-OH-tamoxifen treatment. **d**, Real-time proliferation of *Rosa-Cre^{ERT2};Daxx^{flox/flox}* and *Rosa-Cre^{ERT2};Daxx^{wt/ut}* BMDMs monitored for 6 days using IncuCyte S3 system ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA with Sidak's multiple comparisons test, $F_{\text{genotype}}(1,4) = 0.4210$, $P_{\text{genotype}} = 0.5518$). **e, f**, Western blot and quantification of *Daxx*, *Stat1*, *p-Stat1* and *MDA5* in *Rosa-Cre^{ERT2};Daxx^{flox/flox}* and *Rosa-Cre^{ERT2};Daxx^{wt/ut}* BMDMs after 6 h Poly I:C or LPS stimulation ($n = 4$ independent preparations per group, comparison by ordinary two-way ANOVA with Sidak's multiple comparisons test: for *Daxx*, $F = 31.81$, $P_{\text{PBS Daxx WT vs Daxx KO}} = 0.0052$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} < 0.0001$, $P_{\text{LPS Daxx WT vs Daxx KO}} < 0.0001$; for *Stat1*, $F = 23.16$, $P_{\text{PBS Daxx WT vs Daxx KO}} < 0.0001$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} < 0.0001$, $P_{\text{LPS Daxx WT vs Daxx KO}} < 0.0001$; for *p-Stat1*, $F = 3.52$, $P_{\text{PBS Daxx WT vs Daxx KO}} = 0.6584$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} = 0.0354$, $P_{\text{LPS Daxx WT vs Daxx KO}} = 0.0005$; for *MDA5*, $F = 5.178$, $P_{\text{PBS Daxx WT vs Daxx KO}} = 0.1522$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} = 0.4146$, $P_{\text{LPS Daxx WT vs Daxx KO}} = 0.003$). **g**, IFN- β secretion measured by ELISA in *Daxx* WT and *Daxx* KO BMDMs after 6h-Poly I:C or LPS stimulation (left panel: $n = 6$ independent preparations


per group, comparison by ordinary two-way ANOVA with Sidak's multiple comparisons test: $F = 30.04$, $P_{\text{PBS Daxx WT vs Daxx KO}} > 0.9999$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} < 0.0001$); or following *Stat1* inhibitor pretreatment for 24 h before Poly I:C stimulation (right panel, $n = 3$ independent preparations per group, comparison by ordinary two-way ANOVA with Sidak's multiple comparisons test: $F = 93.72$, $P_{\text{PBS Daxx WT vs Daxx KO}} > 0.9999$, $P_{\text{Stat1 inh. Daxx WT vs Daxx KO}} > 0.9999$, $P_{\text{PolyI:C Daxx WT vs Daxx KO}} < 0.0001$, $P_{\text{PolyI:C+Stat1 inh. Daxx WT vs PDaxx KO}} < 0.0001$). **h, i**, Western blot and quantification analysis of *Daxx*, *Stat1*, and *p-Stat1* in *Rosa-Cre^{ERT2};Daxx^{flox/flox}* and *Rosa-Cre^{ERT2};Daxx^{wt/ut}* BMDMs following LPS stimulation for the indicated times ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA with Tukey's multiple comparisons test: for *Daxx*, $F = 24.98$, $P_{0\text{h Daxx WT vs Daxx KO}} = 0.6021$, $P_{0.5\text{h Daxx WT vs Daxx KO}} = 0.0433$, $P_{3\text{h Daxx WT vs Daxx KO}} = 0.0002$, $P_{6\text{h Daxx WT vs Daxx KO}} < 0.0001$, $P_{24\text{h Daxx WT vs Daxx KO}} < 0.0001$, $P_{3\text{h Daxx WT vs 0h Daxx WT}} = 0.0003$; for *Stat1*, $F = 1.231$, $P_{0\text{h Daxx WT vs Daxx KO}} = 0.0003$, $P_{0.5\text{h Daxx WT vs Daxx KO}} = 0.027$, $P_{3\text{h Daxx WT vs Daxx KO}} = 0.003$, $P_{6\text{h Daxx WT vs Daxx KO}} = 0.0002$, $P_{24\text{h Daxx WT vs Daxx KO}} = 0.0017$; for *p-Stat1*, $F = 5.179$, $P_{3\text{h Daxx WT vs Daxx KO}} = 0.0001$, $P_{6\text{h Daxx WT vs Daxx KO}} = 0.034$, $P_{24\text{h Daxx WT vs 2Daxx KO}} = 0.3201$; for *p-Stat1/Stat1*, $F = 0.05768$, $P_{3\text{h Daxx WT vs Daxx KO}} = 0.5658$, $P_{6\text{h Daxx WT vs Daxx KO}} = 0.9001$, $P_{24\text{h Daxx WT vs Daxx KO}} = 0.8529$). **j**, IFN- β and TNF- α concentrations in the BMDM supernatants measured by ELISA following LPS stimulation for the indicated times ($n = 3$ independent preparations per group, comparison by ordinary two-way ANOVA with Sidak's multiple comparisons test: for IFN- β , $F = 18.17$, $P_{0\text{h Daxx WT vs Daxx KO}} > 0.9999$, $P_{0.5\text{h Daxx WT vs Daxx KO}} = 0.9975$, $P_{3\text{h Daxx WT vs Daxx KO}} < 0.0001$, $P_{6\text{h Daxx WT vs Daxx KO}} < 0.0001$, $P_{24\text{h Daxx WT vs Daxx KO}} < 0.0001$; for TNF- α , $F = 9.169$, $P_{0\text{h Daxx WT vs Daxx KO}} > 0.9999$, $P_{0.5\text{h Daxx WT vs Daxx KO}} = 0.9917$, $P_{3\text{h Daxx WT vs Daxx KO}} = 0.1903$, $P_{6\text{h Daxx WT vs Daxx KO}} = 0.129$, $P_{24\text{h Daxx WT vs Daxx KO}} < 0.0001$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 4 | See next page for caption.

Extended Data Fig. 4 | Single cell mRNA sequencing reveals distinct subpopulation of microglia associated with *Daxx* loss. **a**, UMAP plot showing 13 distinct clusters of microglia cells (8922 cells) identified with different colors. **b**, UMAP plot showing the distinct microglia and macrophage clusters isolated from *Cx3cr1-Cre^{ERT2};Daxx^{ut/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* mice. **c**, Bar plot showing percentage of microglia distribution in each cluster identified in **a**. **d**, Bar plot showing percentage of microglia cells for each sample per cluster identified in **a**; The root clusters were chosen based on the highest percentage of cells at 3dpi – cluster 0 for *Cx3cr1-Cre^{ERT2};Daxx^{ut/ut}* microglia and cluster 5 for *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* microglia. **e**, Dot plot showing homeostatic, proliferative and INF-response gene signatures for microglia isolated from each genotype. **f**, Violin plots showing gene expression of homeostatic, proliferation, INF-response markers and E14.5 cluster 3 signatures⁴⁶ in *in vivo* microglia isolated from each genotype. The black line indicates the median expression/ module


score calculated using the AddModuleScore() function in Seurat; (Statistical significance was assessed by pairwise two-sided Wilcoxon rank-sum tests using the geom_signif function (ggsignif R package) for the given comparisons, no correction for multiple testing; for Homeostatic microglia markers, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} < 2.22e-16$; for IFN-responsive microglia markers, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} < 2.22e-16$; for proliferation markers, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} = 1.7e-05$; for E14.5 microglia cluster 3, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} < 2.22e-16$; for OA2, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} < 2.22e-16$; for OA3, $P_{3dpi} < 2.22e-16$, $P_{1wpi} < 2.22e-16$, $P_{8wpi} = 0.86$). **g**, Feature plots showing *Mki67* and *Nestin* gene expression in the microglial cells across all clusters. **h**, Bar plot showing percentage of cell cycle phases of microglia from *Cx3cr1-Cre^{ERT2};Daxx^{ut/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* mice at 3dpi, 1wpi and 8wpi. Asterisks (*) indicate statistical significance: *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | Loss of *Daxx* leads to lysosome-associated ApoE expression and dystrophic neurites in older mice. **a**, UMAP showing *ApoE* gene expression in the microglia across several clusters. **b**, Dot plot showing cells in each cluster ordered across Pseudotime and colored depending on their *ApoE* expression. **c**, violin plot showing *ApoE* gene expression in the microglia across all clusters. The black line indicates the median expression/ module score calculated using the `AddModuleScore()` function in Seurat; (Statistical significance was assessed by pairwise two-sided Wilcoxon rank-sum tests using the `geom_signif` function (ggsignif R package) for the given comparisons, no correction for multiple testing; $P_{12\text{ vs }0} < 2.22\text{e-}16$, $P_{12\text{ vs }5} = 0.007$, $P_{12\text{ vs }8} = 0.46$, $P_{12\text{ vs }2} < 2.22\text{e-}16$, $P_{12\text{ vs }7} < 2.22\text{e-}16$). **d**, Representative confocal images of Iba1 and ApoE double immunostaining in the cortex of *Cx3cr1-Cre^{ERT2};Daxx^{wt/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flax/flax}* mice at 1ypi ($n = 3$ mice for each genotype); White arrowheads


indicate accumulated ApoE protein in microglia; yellow arrowheads indicate accumulated ApoE in dendrite of microglia. **e**, Representative confocal images of Iba1, ApoE and Lamp1 triple immunostaining in the hilus of *Cx3cr1-Cre^{ERT2};Daxx^{wt/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flax/flax}* mice at 1ypi ($n = 3$ mice for each genotype); White arrowheads indicate the colocalization of ApoE and Lamp1 in the cell body of microglia; yellow arrowheads indicate the colocalization of ApoE and Lamp1 in the dendrite of microglia. **f**, Representative confocal images of SMI31 and NeuN double immunostaining in hippocampus of *Cx3cr1-Cre^{ERT2};Daxx^{wt/ut}* and *Cx3cr1-Cre^{ERT2};Daxx^{flax/flax}* mice at 1ypi ($n = 3$ mice for each genotype); Dashed boxes in the left panel identify high-magnification images of SMI31 staining (right panel); Arrowheads indicate the axonal aggregates. Asterisks (*) indicate statistical significance: ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | Changes in gene expression upon *Daxx* loss in microglia, NPC and KLS cells. **a**, Left panel: Genotyping of wild type and *Daxx*-floxed neuron progenitor cells (NPC) after transfection with the pMSCV-Cre construct (Cre recombinase) *ex vivo*. Arrows indicate the wild-type (226 bp), floxed (350 bp) and recombined alleles (600 bp); right panel: western blots showing *Daxx* protein expression after *Daxx* deletion or restoration of *Daxx* expression in *Daxx*-floxed NPCs ($n = 3$ independent preparations for each group). **b**, Venn diagram showing the overlap of differentially upregulated genes (DEGs) in *Cx3cr1*-Cre^{ERT2}, *Daxx*^{flox/flox} microglia, *Daxx* knockout neuron progenitor cells (NPC) and *Daxx*-deficient bone marrow multipotent progenitors²⁷ (KLS: c-kit⁺, Lin⁻, Sca-1⁺); The overlap of gene sets was evaluated using two-sided generalized


hypergeometric test implemented in the *SuperExactTest* R package ($P = 2.29 \times 10^{-15}$ for 34 upregulated genes). **c**, **d**, Heatmap and gene ontology analysis (GO) for 34 overlapping genes in **c**; Statistical significance of GO analysis was assessed using a two-sided hypergeometric test implemented in the *clusterProfiler* R package, and P values were adjusted for multiple testing using the Benjamini–Hochberg False Discovery Rate (FDR) procedure. **e**, Genome browser visualization of ATAC-seq, RNA-seq and ChIP-seq in *Daxx*-deficient cells and control cells around *ApoE* loci; Yellow region highlights the differential ATAC peaks and ChIP peaks overlapping with candidate cis-Regulatory Elements (cCREs); Brown region highlights *ApoE* loci.



Extended Data Fig. 7 | *Daxx* deficiency causes upregulation of apoptotic genes, elevated γ H2AX and abnormal nuclear morphology in microglia.

a, Genome browser tracks of RNA-seq at gene loci for *Bax*, *Bak1*, *Cdkn1a*, *Pml* in microglia isolated from *Cx3cr1-Cre^{ERT2};Daxx^{wt/wt}* and *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* mice at 3dpi. **b**, Dot plot showing gene expression of *Parp1*, *Rad50*, *Rps27l*, *Bak1*, *Bax* and *Cdkn1a* in microglia isolated from each genotype. **c**, **d**, Representative confocal images and quantification of Iba1 and γ H2AX double immunostaining in brain sections of *Cx3cr1-Cre^{ERT2};Daxx^{flox/flox}* ($n = 4$ mice) and *Cx3cr1-Cre^{ERT2};Daxx^{wt/wt}* mice ($n = 3$ mice) at 3dpi (comparison by two-tailed unpaired Student's t test, $P = 0.0453$). **e**, Representative confocal images of DAPI and Iba1 immunostaining display abnormal nucleus morphology in *Cx3cr1-Cre^{ERT2}*;

Daxx^{flox/flox} microglia ($n = 3$ mice for each genotype). **f**, **g**, Western blot and quantification analysis of Daxx and Pml in *Rosa-Cre^{ERT2};Daxx^{flox/flox}* BMDMs (KO) and *Rosa-Cre^{ERT2};Daxx^{wt/wt}* BMDMs (Ctrl) after 0.5h-, 3h-, 6h- and 24h-LPS stimulation ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA $F = 4.174$, $P = 0.0167$, Tukey's multiple comparisons test: $P_{0h \text{ Daxx WT vs } 0h \text{ Daxx KO}} = 0.0448$, $P_{0.5h \text{ Daxx WT vs } 0.5h \text{ Daxx KO}} = 0.0307$, $P_{3h \text{ Daxx WT vs } 3h \text{ Daxx KO}} = 0.1152$, $P_{6h \text{ Daxx WT vs } 6h \text{ Daxx KO}} = 0.5129$, $P_{24h \text{ Daxx WT vs } 24h \text{ Daxx KO}} = 0.0449$, $P_{6h \text{ Daxx KO vs } 24h \text{ Daxx KO}} = 0.0174$). β -actin was used as an internal loading control. Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.




Extended Data Fig. 8 | See next page for caption.

Extended Data Fig. 8 | Effect of combined loss of *Daxx* and *Pml* on microglia morphology and activation markers. a-c, Representative confocal images,


quantification of Iba1 and CD68 immunostaining and morphological quantification of Iba1⁺ cells in the hippocampus of *Cx3cr1-Cre^{ERT2};Daxx^{wt/wt}* (WT, $n = 4$ mice), *Cx3cr1-Cre^{ERT2};Pml^{fllox/fllox}* (Pml KO, $n = 3$ mice), *Cx3cr1-Cre^{ERT2};Daxx^{fllox/fllox}* (Daxx KO, $n = 3$ mice) and *Cx3cr1-Cre^{ERT2};Daxx^{fllox/fllox};Pml^{fllox/fllox}* (DKO, $n = 3$ mice) at 1wpi (Comparison by ordinary one-way ANOVA with Tukey's multiple comparisons test: for CD68 intensity, $F = 19.57$, $P_{WT \text{ vs Daxx KO}} = 0.0013$, $P_{WT \text{ vs DKO}} = 0.0029$; for Pearson correlation, $F = 9.74$, $P_{WT \text{ vs Daxx KO}} = 0.0337$, $P_{WT \text{ vs Daxx/Pml DKO}} = 0.0066$); for Iba1⁺ cells, $F = 76.04$, $P_{WT \text{ vs Daxx KO}} < 0.0001$, $P_{Daxx KO \text{ vs DKO}} < 0.0001$; for Ramification, $F = 9.952$, $P_{WT \text{ vs Daxx KO}} = 0.0042$, $P_{Daxx KO \text{ vs Pml KO}} = 0.0245$; for branches, $F = 8.925$, $P_{WT \text{ vs Daxx KO}} = 0.0485$, $P_{Pml KO \text{ vs DKO}} = 0.0313$; for

junctions, $F = 9.137$, $P_{WT \text{ vs Daxx KO}} = 0.037$, $P_{Pml KO \text{ vs DKO}} = 0.0305$). **d, e**, Representative confocal images and quantification of Iba1 and CD68 immunostaining in the hippocampus of *Cx3cr1-Cre^{ERT2};Daxx^{wt/wt}* ($n = 4$ mice), *Cx3cr1-Cre^{ERT2};Pml^{fllox/fllox}* ($n = 3$ mice), *Cx3cr1-Cre^{ERT2};Daxx^{fllox/fllox}* ($n = 3$ mice), and *Cx3cr1-Cre^{ERT2};Daxx^{fllox/fllox};Pml^{fllox/fllox}* ($n = 3$ mice) at 1wpi. Bottom panels showing high-magnification images in dashed box. (Comparison by ordinary one-way ANOVA with Tukey's multiple comparisons test: for CD68 intensity, $F = 9.915$, $P_{WT \text{ vs Pml KO}} = 0.3467$, $P_{Daxx KO \text{ vs DKO}} = 0.0471$; for Pearson correlation, $F = 51.14$, $P_{WT \text{ vs Pml KO}} = 0.0361$, $P_{WT \text{ vs Daxx KO}} = 0.0006$, $P_{Daxx KO \text{ vs DKO}} = 0.0024$, $P_{Pml KO \text{ vs DKO}} < 0.0001$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 9 | Elevating *Daxx* expression in neural stem/progenitor cells inhibits cell senescence. **a, b**, Representative confocal images of *Daxx* and quantification of *Daxx* intensity in the cultured neural stem/progenitor cells (NPCs) transfected with empty vector (EV NPCs) or flag-*Daxx* lentiviruses (*Daxx*-overexpression (OE) NPCs) at passage 5 (P5), P10 and P15 ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA $F = 2.574$, $P = 0.1371$; Sidak's multiple comparisons test: $P_{P5\text{ EV vs }P5\text{ Daxx-OE}} < 0.0001$, $P_{P10\text{ EV vs }P10\text{ Daxx-OE}} = 0.0497$,

$P_{P15\text{ EV vs }P15\text{ Daxx-OE}} = 0.0034$, $P_{P5\text{ Daxx-OE vs }P15\text{ Daxx-OE}} = 0.036$). **c, d**, Representative confocal images and quantification of beta-galactosidase activity in the NPCs at P5, P10, P13 and P15 ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA, $F = 117.7$, $P < 0.0001$; Sidak's multiple comparisons test: $P_{P5\text{ EV vs }P5\text{ Daxx-OE}} = 0.4226$, $P_{P10\text{ EV vs }P10\text{ Daxx-OE}} = 0.4226$, $P_{P13\text{ EV vs }P13\text{ Daxx-OE}} = 0.002$, $P_{P15\text{ EV vs }P15\text{ Daxx-OE}} = 0.0009$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.



Extended Data Fig. 10 | Exogenous Daxx reduces γ H2AX, *ApoE* and *Cdkn1a* expression in neural stem/progenitor cells. a, b, Representative confocal images of γ H2AX and quantification of γ H2AX signal in the cultured neural progenitor cells (NPCs) transfected with empty vector (EV NPCs) or flag-*Daxx* lentiviruses (*Daxx*-OE NPCs) at passage 5 (P5) and P15 (for intensity of γ H2AX, $n = 3$ independent preparations per group, comparison by two-way RM ANOVA with Sidak's multiple comparisons test: $F = 12.84$, $P_{P5\text{ EV vs Daxx-OE}} = 0.0443$, $P_{P15\text{ EV vs Daxx-OE}} = 0.0003$; for γ H2AX puncta, analysis included 172 nucleus (P5 EV), 331 nucleus (P5 *Daxx*-OE), 1081 nucleus (P15 EV), and 433 nucleus (P15 *Daxx*-OE) from 3 independent preparations per group, comparison by two-way RM ANOVA with Tukey's multiple comparisons test: $F = 35.89$, $P_{P5\text{ EV vs Daxx-OE}} = 0.0407$, $P_{P15\text{ EV vs Daxx-OE}} < 0.0001$). **c, d,** Western blot analysis and quantification of

Daxx and *ApoE* proteins expression in lysates of cultured NPCs at P5 and P15 ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA with Fisher's LSD multiple comparisons test, for *Daxx*: $F = 13.82$, $P_{P5\text{ EV vs Daxx-OE}} < 0.0001$, $P_{P15\text{ EV vs Daxx-OE}} = 0.0098$; for *ApoE*: $F = 5.853$, $P_{P5\text{ EV vs Daxx-OE}} = 0.031$, $P_{P15\text{ EV vs Daxx-OE}} = 0.0006$). **e,** qPCR for genes expressions in NPCs at P5 and P15 ($n = 3$ independent preparations per group, comparison by two-way RM ANOVA with Fisher's LSD multiple comparisons test, for *Daxx*: $F = 36.28$, $P_{P5\text{ EV vs Daxx-OE}} = 0.0069$, $P_{P15\text{ EV vs Daxx-OE}} = 0.001$; for *ApoE*: $F = 1.709$, $P_{P5\text{ EV vs Daxx-OE}} = 0.0005$, $P_{P15\text{ EV vs Daxx-OE}} < 0.0001$; for *Cdkn1a*: $F = 0.56$, $P_{P5\text{ EV vs Daxx-OE}} = 0.0481$, $P_{P15\text{ EV vs Daxx-OE}} = 0.0101$). Data are presented as mean $\pm$ s.e.m. Asterisks (*) indicate statistical significance: * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$; n.s. indicates not significant.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☐	☒ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☒	☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☐	☒ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Imaging data was collected using Zeiss 700 or Zeiss 900. Blots was imaged using LICOR OXF-2068 or ChemiDoc XRS+ system bulk RNA-seq, ATAC-seq, CUT&Tag and scRNA-seq data were collected by Illumina NexSeq 500, Illumina NovaSeq 6000, Illumina NovaSeq X Plus system.
Data analysis	All graphical and statistical analyses were performed using: ImageJ (v1.5e), ImageJ (v2.14), Imaris v9.8 software, Prism9 software (Graphpad Software,USA) and microsoft Excel. R package Seurat (v.1.1), Bcl2fastq2 (V2.20), STAR (v. 2.6.1b), STAR (v2.7.1), Dropseq-tools (v. 2.0.0), Bioconductor package celda (1.10.0), monocle3 (1.0.0), DESeq2 (ver. 1.34.0), TrimGalore(v. 0.6.10), Subread (v. 2.0.3), sklearn python package, ChIPpeakAnno (ver. 3.28.1), atacseq pipeline (ver. 1.2.2), ChIPseeker R package (v. 1.26.2), SQUIRE pipeline (ver. 0.9.9.92), clusterProfiler R package (v. 3.18.1), deepTools (v. 3.5.1) package , BWA-MEM (v0.7.8-r455), SAMtools (v1.11), deepTools (v3.5.3), HOMER (v5.1) were used for bio-informatic analysis. Please see Methods section in manuscript for further detail.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All original uncropped western blots in this study are provided in the Source Data as Source Data Raw blots. The raw and processed bulk RNA-Seq, ATAC-seq, scRNA-seq and CUT&Tag data are deposited on GEO (GSE255329, GSE276607, GSE267028, GSE272828, GSE309782). The following datasets containing expression analysis from mice microglia and neuronal cells were re-analyzed for this study: GEO accession number GSE121654 (Hammond et al.), GSE207932 (Li et al.), GSE298386 (Li et al.), GSE79819 (Matcovitch-Natan), GSE52564 (Zhang et al.), E-MTAB-5077 (Buttgereit et al.), GSE226092 (Fixen et al.), GSE119309 (Gerber et al.), GSE150169 (Zhan et al.). Other data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

Sex was used as a covariate in all statistical models.

Reporting on race, ethnicity, or other socially relevant groupings

The human study population was overwhelmingly of European descent (>95%). Therefore, meaningful race or ethnicity-stratified analyses were not possible. Moreover, based on the animal findings, it was not expected that race, ethnicity or other social groupings would act as modifiers of the relation between DAXX and RTE expression levels.

Population characteristics

The current analysis was conducted on a total of 2922 participants of the Rhineland Study. Age, sex and smoking status data were derived from self-reports.

Recruitment

The human data were derived from the Rhineland Study, an ongoing community-based cohort study in Bonn, Germany. All inhabitants aged 30 years and above of two geographically defined areas were invited to participate in the Rhineland Study. The sole exclusion criterion for participation in the Rhineland Study was insufficient command of the German language to provide informed consent. For the present study we included the subset of all Rhineland Study participants in whom transcriptomic data were available.

Ethics oversight

The Rhineland Study was approved by the ethics committee of the University of Bonn, Medical Faculty. The Rhineland Study is carried out in accordance with the recommendations of the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) standards (ICH-GCP). Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences

☐ Behavioural & social sciences

☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No statistical method was used to predetermine sample size. Sample size was chosen based on our previous studies using the same types of assays (Gerber et al. 2021, Nat Cell Biol.).
In vitro studies used a standard of at least N=3 independent experiments were always used.
Histology were performed on at least 3 mice per group.
Sample sizes for behavioral experiments were determined based on the current standard, as the minimum amount of mice required to detect significance with an alpha rate set at 0.05 in a standardly powered experiment.

Data exclusions

No data was excluded from the analysis.

Replication

Experiments run on the same day always included control and knock-out mice. Most experiments were performed on at least 3 independent trials. The attempts of replication were successful and no experiment was excluded. All samples and mice were handled following the same protocols. The number of biological replicates for Rose-CreERT;H3.3Afl/fl,H3.3B-/- mouse is limited to 2 mice per genotype, since tissues from this mouse line were obtained from our collaborators at Cornell, who at the time had limited animal availability within the timeframe of our study. Data from enzymatic dissociation-induced artificial genes were part of a control experiment suggested by the reviewer, which was based on a limited number of biological replicates due to the turnaround time of our revision. Bulk RNAseq at 8wpi were run with 2 biological

replicates per genotype/condition, and scRNAseq data were run with 2 biological replicates for 3dpi WT, 1wpi Daxx KO and 8wpi, and 1 replicate for 3dpi Daxx KO and 1wpi WT; CUT&Tag data were run with 3 biological replicates for H3K9me3 Daxx KO and H3.3 WT, and 2 biological replicates for H3K9me3 WT and H3.3 Daxx KO.

Randomization Sample allocation was random and mice for experiments were randomly chosen based on availability of the right genotypes.

Blinding During all animal studies, animals are labeled by identification number and genotype is unknown to experimenter during testing. For all in vitro studies, due to the relatively small number of biological replicates in each experiment, both control and KO groups are known to the experimenter. For all other analyses, the experiments were blinded to the genotype or treatment until completion of statistical analyses.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| ☐ | ☒ Antibodies |
| ☒ | ☐ Eukaryotic cell lines |
| ☒ | ☐ Palaeontology and archaeology |
| ☐ | ☒ Animals and other organisms |
| ☒ | ☐ Clinical data |
| ☒ | ☐ Dual use research of concern |
| ☒ | ☐ Plants |

Methods

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| ☒ | ☐ ChIP-seq |
| ☒ | ☐ Flow cytometry |
| ☒ | ☐ MRI-based neuroimaging |

Antibodies

Antibodies used

Mouse monoclonal anti-Beta Amyloid (1:1000, 6E10, Covance Cat#SIG-39300)
 Mouse monoclonal anti-β-actin (1:1000, Sigma-Aldrich Cat#A1978)
 Rabbit monoclonal anti-ApoE (1:1000, Abcam, Cat#AB183597)
 Mouse monoclonal anti-Bassoon (1:800, Enzo Cat#ADI-VAM-PS003-F)
 Rat monoclonal anti-CD68 (1:200, Biolegend, Cat#137001; FA-11)
 Rabbit polyclonal anti-Cleaved Caspase-3 (Cell Signaling, Cat#9661)
 Rabbit polyclonal anti-Daxx (1:300, Santa Cruz Biotechnology, Cat#sc-7152)
 Rabbit polyclonal anti-Daxx (1:1000, Abcam, Cat# Ab32140)
 Chicken polyclonal anti-GFAP (1:300, Abcam, Cat#ab4674)
 Rabbit polyclonal anti-γH2AX (1:1000, Cell Signaling, Cat#9718)
 Rabbit polyclonal anti-H2AX (1:1000, Cell Signaling, Cat#2595)
 Rabbit polyclonal anti-H3.3 (1:20, Millipore Cat#09-898)
 Rabbit polyclonal anti-H3K9me3 (1:50, Active Motif, Cat#39062)
 Chicken polyclonal anti-Homer1 (1:500, Synaptic Systems, Cat#160006)
 Guinea pigs polyclonal anti-Iba1 (1:500, Synaptic Systems, Cat#234004)
 Rabbit monoclonal anti-Ki67 (1:300, Abcam, Cat#ab16667)
 Rat monoclonal anti-Lamp1 (1:300, Abcam Cat#ab25245)
 Rat monoclonal anti-MBP (1:300, Abcam Cat#ab7349)
 Rabbit polyclonal anti-MDA5 (1:1000, Thermo Fisher Scientific, Cat#PA5-20337)
 Rabbit polyclonal anti-Mavs (1:1000, Abcam, Cat# Ab31334)
 Chicken polyclonal anti-NeuN (1:500, Abcam, Cat#ab134014)
 Mouse monoclonal anti-Pml (1:1000, Sigma-Aldrich, Cat#05-718)
 Rabbit polyclonal anti-p53 (1:1000, Leica Biosystems, Cat#NCL-L-P53-CM5P)
 Rabbit polyclonal anti-p-p53 (1:1000, Cell Signaling, Cat#9284)
 Rabbit polyclonal anti-PSD95 (1:500, Synaptic Systems, Cat#124003)
 Rabbit polyclonal anti-Stat1 (1:1000, Cell Signaling, Cat#9172S)
 Rabbit polyclonal anti-p-Stat1 (1:1000, Cell Signaling, Cat#9167S)
 Mouse monoclonal anti-SMI31 (1:200, Biolegend, Cat#801602)
 Rabbit monoclonal anti-Sox9 (1:300, Abcam, Cat#ab185230)
 Rabbit polyclonal anti-synaptophysin (1:500, Cell Signaling, Cat#4329)
 Rabbit monoclonal anti-Trim28 (1:1000, Abcam Cat#ab10484)

Validation

All antibodies used are commercially available antibodies and detailed validation information of each antibody can be found from the manufacturer.

Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	C57BL/6 Daxx-floxed mice and PML-floxed mice were generated by Taconic Artemis (Cologne, Germany). IFNAR KO mice were purchased from The Jackson Laboratory (stock no. 028228). Floxed Daxx mice were crossed with C57BL/6J Cx3cr1CreERT2 mice (JAX 020940), C57BL/6J Rosa26CreERT2 mice (JAX 008463). C57BL/6N floxed Hira mice were crossed with C57BL/6J Cx3cr1CreERT2 mice (JAX 020940). Floxed H3.3A,H3.3B-/- mice were crossed with C57BL/6J Rosa26CreERT2 mice (JAX 008463). To induce Cre activation, Rosa26-CreERT2 or Cx3cr1-CreERT2 positive mice at 6-7-week-old age was administrated with 80 mg/kg/day tamoxifen (T5648, Sigma-Aldrich) via oral gavage for five consecutive days. For polyinosinic-polycytidylic acid stimulation, mice were injected by i.p. with 300 µg of polyinosinic-polycytidylic acid (Poly I:C) for 5 or 12 hours. Mice were maintained on a 12-hour light/dark cycle with ad libitum access to regular chow food (ssniff Spezialdiäten GmbH).
Wild animals	The study did not involve wild animals
Reporting on sex	Mice of both genders were used in this study. Data of in vitro microglia or BMDM isolated from both male and female were pooled. Behavior tests were performed only on male mice.
Field-collected samples	The study did not involved field-collected samples.
Ethics oversight	All experimental procedures were approved by Landesamt für Verbraucherschutz und Ernährung Nordrhein-Westfalen (LAVE) (formerly Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV)) under protocols 81-02.04.2016.A486, 81-02.04.2020.A346 and 81-02.04.2021.A019.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks	This study did not involve plants
Novel plant genotypes	This study did not involve plants
Authentication	This study did not involve plants